go green, go online! jddonlinedl.jddonline.com/pdfs/indexes/2011_subject_index.pdf · dutasteride...

Copyright © 2011 INDEX OF ARTICLES Journal of Drugs in Dermatology

SU

BJE

CT

IND

EX

AAbatacept, randomized double-blind placebo-

controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342

AbobotulinumtoxinA (ABO)in combined treatment for skin rejuvenation

and soft tissue augmentation of aging face, 125

comparing clinical attributes of ABO and onabotulinumtoxinA utilizing Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148

AC-820 (nalfurafine HCl), randomized-withdrawal phase 3 study on safety and efficacy in hemodialysis and uremic pruritus (CTR), 91

Açai berry, aesthetic benefits of natural ingredients in skin care, s11 (September)

Acitretinassessment of national trends in treatment of

psoriasis, 873depression associated with, 409in dermatology, review of literature on, 772low-dose, efficacy and side effects in psoriasis

(CTR), 95Acne vulgaris

Acanya gel acne therapy available in pump (PP), 1479

adapalene gel in treatment of atrophic acne scars (CTR), 96

advantages of oral contraceptives and spironolactone for women with (DP), 941

CME: demystifying acne algorithms, s5 (June), s24 (June), s26 (June)

combination treatment for moderate-to-severe (CTR), 90

comparing OTC treatment to prescription regimen (CTR), 90, 312

dose-ranging study on safety and efficacy of IDP-107 in (CTR), 426

efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and, 586

Epiduo pediatric acne study (CTR), 90, 312Eucerin launches campaign in Europe and

Asia (PP), 1076

evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907

evidence-based review on fixed-combination therapy and topical retinoids in, 636

fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI (DP), s6 (December)

Gly-Sal Acne Body Spray (PP), 434importance of vehicles in topical therapy, s17

(June)inflammation in rosacea and acne,

implications for patient care, 614introduction to demystifying acne algorithms

supplement (editorial), s7 (June)isotretinoin does not prolong QT intervals

and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

La Roche-Posay introduces new products (PP), 938

medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766

new information regarding pathogenesis of, 582

patient experience and management of dryness and irritation from treatment, 605

in patients with skin of color, s13 (June)randomized study of dapsone gel 5% in

combination with tazarotene cream 0.1% in, 783

resveratrol-containing gel for (PP), 434rethinking treatment in severe patient, s8

(June)safety and efficacy of clindamycin phosphate

1.2%–benzoyl peroxide 3% fixed-dose combination gel for, 1382

safety and efficacy of micronized tretinoin 0.05% gel in adolescent, 647

self-treatment of mild-to-moderate facial acne with blue light treatment system, 596

strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)

study comparing Aczone plus Differin to Duac

plus Differin in severe facial acne (CTR), 312

study of new drug treatment for (CTR), 687ten tips for treatment in Fitzpatrick skin types

IV–VI (BC), 654why are dermatologists still talking about

acne? because so many people have it, and we are always seeking better ways to manage it (editorial), 575

Actinic cheilitis (AC), treatment by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240

Actinic keratoses (AK)comparison of cryotherapy and imiquimod

for, lesion clearance, safety, and skin quality outcomes in, 1432

effect of retinoid pretreatment on outcomes of photodynamic therapy for AK of hand and forearm, 1124

Graceway receives FDA approval for Zyclara Cream 2.5% (PP), 1076

imiquimod cream in combination with cryotherapy in treatment of hypertrophic AK (CTR), 426

long-term sustained complete clearance of AK of face or balding scalp after imiquimod treatment, 165

nonablative 1927 nm fractional resurfacing for (PP), 103

prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for, 372

randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for AK of upper extremities, 1049

safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53

treatment with imiquimod cream followed by photodynamic therapy (CTR), 426

trends in treatment of, 16Acupressure for pruritus in atopic dermatitis

(CTR), 90Adalimumab

Mycobacterium fortuitum infection following adalimumab treatment for psoriasis

2011 SUBJECT INDEXLetters after article titles refer to the following: BC = Brief Communication; CR = Case Reports; CTR = Clinical Trial Review; DP = DermPearls; NVR = News, Views, and Reviews; PP = Pipeline Previews; RR = Resident Rounds; RS = Resident Spotlight

As part of the JDD green initiative, starting in 2009, the author and subject indexes will be published exclusively online. In previous years these have been printed in the December Issue, but for your convenience and for

environmental consciousness, the indexes will now be available electronically.

Go Green, Go Online!

JDDonline.com


SU

BJE

CT

IND

EX

and subsequent complication-free treatment with alternate TNF-a blockers (CR), 914

and narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366

open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to, 396

treatment of recalcitrant generalized granuloma annulare with (CR), 1466

Adapaleneadapalene gel 0.3% in atrophic acne scars

(CTR), 96Epiduo pediatric acne study (CTR), 90, 312rethinking treatment of acne in severe patient,

s8 (June)study comparing Aczone plus Differin to Duac

plus Differin in severe facial acne (CTR), 312

in topical monotherapy for acne, compared to fixed-combination therapy, 636

Adherence to treatmentin once-daily therapy with sertaconazole

nitrate for interdigital tinea pedis, 1135

patient experience and management of dryness and irritation from acne treatment affecting, 605

in topical rosacea therapy, vehicle formulations affecting, 627

AEB071, dose finding study assessing psoriasis area and severity index in plaque psoriasis (CTR), 92

Agingclinical evidence for activity of

tetrahydroxypropyl ethylenediamine (THPE) as new anti-aging active cosmetic, 1102

combined treatment for skin rejuvenation and soft-tissue augmentation of aging face, 125

dermal fillers in skin of color population, 494evolution of injectable poly-L-lactic acid from

correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler in, 673

multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352

prospective randomized trial on effects of fluence settings in Er:YAG micropeel for facial photoaging, 179

safety and efficacy of calcium hydroxylapatite for rejuvenation of aging hand, 47

tower technique for injection of hyaluronic acid fillers in, 1277

AIDS. See HIV infection and AIDSAIN457, dose-ranging study in moderate-to-

severe chronic plaque-type psoriasis (CTR), 93

Albert Einstein College of Medicine Unified Division of Dermatology

eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210

intralymphatic histiocytosis associated with orthopedic implants (RR), 1208

program spotlight on Residency Program

(RR), 1122sound-alike and look-alike terms in

dermatology (RR), 1196Alefacept for nephrogenic systemic fibrosis (CR),

922Alexandrite laser

comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in hirsutism, 1255

treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)

Aloe veraaesthetic benefits of natural ingredients in

skin care, s11 (September)in atopic dermatitis and other inflammatory

skin diseases, s6 (September)Aloesin, aesthetic benefits of natural ingredients

in skin care, s11 (September)Alopecia

approvals, long-term safety data, cancer risk, and treatment options in androgenetic alopecia in women (NVR), 98

dutasteride versus placebo and finasteride in men with androgenetic alopecia (CTR), 936

novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795

randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342

role of inflammation and immunity in pathogenesis of androgenetic alopecia, 1404

safety and efficacy of clobetasol propionate 0.05% emollient foam in (CTR), 1077

safety and efficacy study of bimatoprost in women with female pattern hair loss (CTR), 936

scalp hyperkeratosis and alopecia in children of color, 511

START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936

Amazingel compared to other polyacrylamide hydrogels, 1370

AMG 157, safety study in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687

Aminolevulinic acid (ALA)effect of retinoid pretreatment on outcomes

of ALA-PDT for actinic keratosis of hand and forearm, 1124

preliminary results of hidradenitis suppurativa treatment with ALA-PDT, 381

prospective case-based assessment of sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372

randomized blinded bilateral intraindividual vehicle-controlled trial of ALA-PDT and blue light for actinic keratoses of upper extremities, 1049


severe cutaneous reaction to ALA-PDT with blue light (CR), 1057

treatment of actinic cheilitis by ALA-PDT and blue light activation, 1240

Amiodarone, Q-switched laser treatment of amiodarone pigmentation (CR), 1316

Ammonium lactate emollient foam vehicle, salicylic acid 6% in, for scalp psoriasis, 270

Anakinraeffective for severe Muckle-Wells syndrome

(PP), 214pilot study in severe atopic dermatitis (CTR),

313Anal cancer, FDA approves Gardasil to prevent

(PP), 325Anal fissures, FDA approval of Rectiv for pain

associated with (PP), 939Androgens, decrease of insulin growth factor-1

as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793

Anti-inflammatory agentscutaneous reactions to non-steroidal anti-

inflammatory drugs, 1160in natural ingredients, s12 (September)randomized study of dapsone gel 5% in

combination with tazarotene cream 0.1% in acne vulgaris, 783

Antimicrobial drugsantibiotic resistance: an editorial review with

recommendations, 724FDA approves Ceftaroline for MRSA (PP), 104recent advances and future directions in

medical management of skin disease, 28

rethinking treatment of acne in severe patient, s8 (June)

Antioxidantsassessment of antioxidative capacity kinetics

of topical antioxidants, 262complementary antioxidant function of

caffeine and green tea polyphenols in normal human skin fibroblasts, 753

green tea extract protects human skin fibroblasts from reactive oxygen species induced necrosis, 1096

in natural ingredients, s11 (September)Apremilast

open label pilot study in rosacea (CTR), 313phase 2 open-label investigator-initiated study

of safety and efficacy in recalcitrant contact or atopic dermatitis (RS), 928

study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487

Aquamid compared to other polyacrylamide hydrogels, 1370

Aquaphor Healing Ointment compared to prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531

Arbutin, aesthetic benefits of natural ingredients in skin care, s11 (September)

Arrhythmias, isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

L-Ascorbic acid, evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455

Asian patientscommunity-based survey of skin conditions


SU

BJE

CT

IND

EX

and concerns in South Asian Americans, 524

treating lentigines with Q-switched Alexandrite laser in (DP), s14 (December)

ASP015K, study to explore efficacy and safety in moderate-to-severe psoriasis (CTR), 93, 315

Atopic dermatitis (AD)acupressure for pruritus in (CTR), 90bilateral comparison study of pimecrolimus

cream 1% and medical device cream in, 735

bilateral comparison study of pimecrolimus cream 1% and medical device emollient foam in, 666

comparing Cetaphil Restoraderm System versus standard skin care in infants with (CTR), 1486

comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate AD of children, 531

effects of novel fluocinonide cream formulation on skin barrier function in, 171

efficacy, safety, and tolerability of topical nalmefene for pruritus in, 853

efficacy and safety of different concentrations of ZK245186 in (CTR), 313

efficacy of fluocinonide cream 0.1% in reducing itch in (CTR), 1486

natural ingredients for skin care and treatment in, s6 (September)

new body moisturizer increases skin hydration and improves AD symptoms in children and adults, 714

pediatric longitudinal evaluation on long-term safety of Protopic Ointment for (CTR), 1217

phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928

pilot study of Anakinra in severe AD (CTR), 313

recent advances in treatment of, 28safety study of AMG 157 in healthy subjects

and subjects with AD (CTR), 313, 687

sequential ascending dose study on safety and tolerability of REGN668 in (CTR), 314

stratum corneum abnormalities in, s9 (October)

Autoimmune conditionsblisters in (RR), 491bullous pemphigoid after herpes zoster

vaccine administration (CR), 1328effectiveness of topical tacrolimus for vitiligo

in, 507highlights of common autoimmune

connective tissue diseases (RR), 1314

Avotermin in keloids (NVR), 550Axillary hyperhidrosis, same-patient prospective

comparison and literature review of Botox versus Dysport for (CR), 1013

Azelaic acidefficacy and safety of azelaic acid gel

15% in post-inflammatory hyperpigmentation and acne, 586

in topical rosacea therapy, vehicle formulations for, 627

Azficel-TFDA approval of Fibrocell Science LAVIV (PP),

939in nasolabial folds and wrinkles (PP), 325, 939

BB cell lymphoma, diffuse large, associated with

biologic and other investigational agents in psoriasis (CR), 80

Barrier creams, prescription, compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531

Barrier function of skin. See Skin barrier functionBasal cell carcinoma (BCC)

electronic brachytherapy for treatment of (CTR), 206

Genentech submits New Drug Application to FDA for (PP), 1340

study on efficacy and safety of GDC-0449 in (CTR), 206

ulcerated nodular nasal BCC successfully treated with imiquimod 5% cream (letter to the editor), 240

Belimumab, FDA approves Benlysta for lupus erythematosus (PP), 806

Benzocaine, methemoglobinemia risk from benzocaine topical products (PP), 684

Benzoyl peroxideAcanya gel acne therapy available in pump

(PP), 1479in combination treatment for moderate-to-

severe acne (CTR), 90Epiduo pediatric acne study (CTR), 90, 312in fixed-combination therapy for acne,

compared to retinoid monotherapy, 636

patient experience and management of dryness and irritation from acne treatment with, 605


safety and efficacy of clindamycin phosphate 1.2%–benzoyl peroxide 3% fixed-dose combination gel for acne vulgaris, 1382

study comparing Aczone plus Differin to Duac plus Differin in severe facial acne (CTR), 312

Betamethasone dipropionateLEO Pharma launches $0 copay program

for Taclonex plaque psoriasis treatments (PP), 683

topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878

Bexarotene, study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma (CTR), 209

Bicillin-LA versus placebo for chronic plaque-type psoriasis unresponsive to topical medications (CTR), 317

Bimatoprostnovel treatment of female-pattern

androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795

safety and efficacy in women with female pattern hair loss (CTR), 936

Bio-Alcamid compared to other polyacrylamide hydrogels, 1370

Bioflavanoids, randomized placebo-controlled

double-blind study on efficacy of citrus bioflavanoid blend in senile purpura, 718

Biologicsdiffuse large B-cell lymphoma associated with

biologic and other investigational agents in psoriasis (CR), 80

impact on disease and treatment burden of psoriasis, 189

Biopsy diagnosisclinical clues and patterns to help distinguish

cutaneous metastases (NVR), 678, 930

comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078

Bladder cancerclinical clues and patterns in biopsy diagnosis

of cutaneous metastases of (NVR), 678, 930

review of chemopreventative effects of oral retinoids for, 1292

Blisters, autoimmune-mediated (RR), 491Blue light

randomized blinded bilateral intraindividual vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049



severe cutaneous reaction to photodynamic therapy with (CR), 1057

treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240

Botanical productscomparative study of safety and efficacy of

75% mulberry extract oil versus placebo as topical treatment for melasma, 1025

cosmeceutical and nutraceutical horizons, 24evaluation of moisturizing effect of

methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116

randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in wound healing, 1168

Botulinum toxinAllergan cell-based assay for BOTOX (PP), 938in combined treatment for skin rejuvenation

and soft-tissue augmentation of aging face, 125

comparing clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148

cosmeceutical and nutraceutical horizons, 24FDA approves Botox for chronic migraine

(PP), 104FDA approves Xeomin (incobotulinumtoxinA)

for glabellar lines (PP), 1076Frontalis Activity Measurement Standard

as novel contralateral method for


SU

BJE

CT

IND

EX

assessing botulinum neurotoxin type-A activity, 968

in keloid management (NVR), 549long-term efficacy and potencies of botulinum

toxin A and B (PP), 324rapid onset of response and patient-reported

outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39

same-patient prospective comparison and literature review of Botox versus Dysport for primary axillary hyperhidrosis (CR), 1013

Brachytherapy, electronic, for non-melanoma skin cancer treatment (CTR), 206

Breast cancerclinical clues and patterns in biopsy diagnosis

of cutaneous metastases (NVR), 678, 930


Breast reconstructive surgery, case report of pyoderma gangrenosum following treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545

Briakinumab withdrawal from FDA review (PP), 435

Brief Communications (BC)assessor-blinded study of metabolic

syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts, 900

CD70 and Th17 are involved in human contact sensitivity, 1192

community-based survey of skin conditions and concerns in South Asian Americans, 524

decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its reported association with depression in some cases, 793

efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome, 403

ten tips for treating acne vulgaris in Fitzpatrick skin types IV–VI, 654

Broward General Medical Center Residency Training Program

autoimmune-mediated blisters (for the Boards) (RR), 491

case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545

program spotlight on (RR), 467Bupivacaine hydrochloride, Sagent

Pharmaceuticals announces FDA approval of bupivacaine hydrochloride injection (PP), 1478

Burdock, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116

Burnsappearance of burn scars after fractional

carbon dioxide laser treatment (CTR), 96

chemical burn from povidone-iodine (CR), 414multiple facial burns with new Thermage CPT

system (CR), 1320

CCaffeine, complementary antioxidant function of


Calcinosis cutis, ulcerative, novel treatment for, 1042

Calciphylaxis, evaluation of efficacy of lanthanum carbonate in (CTR), 1342

CalcipotrieneFDA approves Sorilux foam (PP), 103LEO Pharma launches $0 copay program

for Taclonex plaque psoriasis treatments (PP), 683


Calcitriolmulti-center open-label study on safety and

efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158

Yin-Yang strategy in new effective repeatable sequential therapy for psoriasis, 831

Calcium hydroxylapatite, management of impending necrosis associated with soft tissue filler injections (CR), 1007

Cardiovascular disease riskmetabolic syndrome and surrogate markers

of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900

psoriasis drugs not linked to increased heart risks (PP), 1215

Case Reports (CR)alefacept therapy for nephrogenic systemic

fibrosis, 922bullous pemphigoid after herpes zoster

vaccine administration, 1328case of lichen planus following Tdap

vaccination, 1067central serous chorioretinopathy associated

with topical corticosteroids in psoriasis, 918

chemical burn from povidone-iodine, 414chloracne-like drug eruption associated with

sorafenib, 1331diffuse large B-cell lymphoma associated with

biologic and other investigational agents in psoriasis, 80

erythema multiforme-like drug reaction to sorafenib, 1462

fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil in pemphigus foliaceus in immunocompromised patient, 418

fixed drug eruption associated with iohexol intravenous contrast media, 802

levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome, 1204

management of impending necrosis associated with soft tissue filler

injections, 1007metallic taste as side effect of topical

fluorouracil, 1201modified Tripier flap for lateral eyelid

reconstruction, 199Mohs micrographic surgery for cutaneous

lymphadenoma, 1324multiple facial burns with new Thermage CPT

system, 1320Mycobacterium fortuitum infection following

adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers, 914

novel KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation, 926

novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution, 795

pigmentary changes in patient treatment with imatinib, 1062

post-herpetic itch resolved with gabapentin, 85

Q-switched laser treatment of amiodarone pigmentation, 1316

regression of internal melanoma metastases after topical application of imiquimod, 302

rituximab dosing in refractory pemphigus vulgaris in adolescent male, 202

same-patient prospective comparison and literature review of Botox versus Dysport for primary axillary hyperhidrosis, 1013

severe cutaneous reaction to photodynamic therapy with blue light, 1057

sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in hepatocellular carcinoma, 308

tamoxifen-induced hirsutism, 799tattoo sites and psoriasis, 1199treatment of peristomal pyoderma

gangrenosum with topical crushed dapsone, 1059

treatment of recalcitrant generalized granuloma annulare with adalimumab, 1466

vesiculobullous variant of adult T-cell leukemia/lymphoma in a Caribbean émigré, 1469

CC-10004 for prurigo nodularis (CTR), 91CD70 and TH17 involvement in human contact

sensitivity (BC), 1192CD07805/47 topical gel, phase 3 efficacy and

study in facial erythema associated with rosacea (CTR), 1216

Ceramidebilateral comparison study of pimecrolimus

cream 1% and ceramide-hyaluronic acid emollient foam in atopic dermatitis, 666

ceramide-containing barrier repair cream compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531

Cetaphil Restoraderm System compared to standard skin care in infants with atopic dermatitis (CTR), 1486

Chamomile in atopic dermatitis and other inflammatory skin diseases, s6 (September)

Cheilitis, actinic, treatment by photodynamic


SU

BJE

CT

IND

EX

therapy with 5-aminolevulinic acid and blue light activation, 1240

Chemical burn from povidone-iodine (CR), 414Chemical peels

in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125

comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with melasma, 1439

Chemoprevention, review of chemopreventative effects of oral retinoids for internal neoplasms, 1292

Chemotherapy, START (Swiss Taxotere Alopecia Prevention Trial) (CTR), 936

Children. See Pediatric dermatologyChitosan, treatment efficacy of triple bandage

compression and chitosan gel in venous leg ulcers, 75

Chloracne-like drug eruption associated with sorafenib (CR), 1331

Chorioretinopathy, central serous, associated with topical corticosteroids in psoriasis (CR), 918

Citrus bioflavanoid blend, randomized placebo-controlled double-blind study on efficacy in senile purpura, 718

Cleansing product in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179

ClindamycinAcanya gel acne therapy available in pump

(PP), 1479in combination treatment for moderate-to-

severe acne (CTR), 90in fixed-combination therapy for acne,

compared to retinoid monotherapy, 636

patient experience and management of dryness and irritation from acne treatment with, 605



Clinical Trial Reviews (CTR)acupressure for pruritus in atopic dermatitis,

90adapalene gel in treatment of atrophic acne

scars, 96Bicillin-LA versus placebo for chronic plaque-

type psoriasis unresponsive to topical medications, 317

burn scar appearance after fractional carbon dioxide laser treatment, 96

CC-10004 for prurigo nodularis, 91clinical trial of Dermacorder for detecting

malignant skin lesions, 317combination treatment for moderate-to-

severe acne, 90comparing Aczone plus Differin to Duac plus

Differin in severe facial acne, 312comparing Cetaphil Restoraderm System

versus standard skin care in infants, 1486

comparing OTC acne treatment to prescription regimen, 90, 312

comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma,

207comparison of retinol 1.0% and tretinoin

0.02% in moderate-to-severe photodamage and wrinkles, 1217

CP-690-550 ointment for chronic plaque psoriasis, 316

dapsone gel 5% for dermatitis herpetiformis, 314

dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery, 208

dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia, 207

dose finding study of AEB071 assessing psoriasis area and severity index in plaque psoriasis, 92

dose-ranging study of AIN457 in moderate-to-severe chronic plaque-type psoriasis, 93

dose-ranging study on safety and efficacy of IDP-107 in acne vulgaris, 426

dutasteride versus placebo and finasteride in men with androgenetic alopecia, 936

effects of pulsed-dyed laser on scar formation, 96

efficacy and safety of different concentrations of ZK245186 in atopic dermatitis, 313

efficacy and side effects of low-dose acitretin in psoriasis, 95

efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis, 1486

electronic brachytherapy for non-melanoma skin cancer treatment, 206

Epiduo pediatric acne study, 90, 312evaluation of efficacy of lanthanum carbonate

in calciphylaxis, 1342gemcitabine and pemetrexed disodium in

advanced mycosis fungoides or Sézary syndrome, 210

imatinib in mucosal or acral/lentiginous melanoma, 208

imiquimod cream in combination with cryotherapy in treatment of hypertrophic actinic keratosis, 426

in vivo confocal microscopy of cutaneous neoplasms and normal skin, 318

lenalidomide in AIDS-related Kaposi sarcoma, 210

lenalidomide in relapsed mycosis fungoides/Sézary syndrome, 209

liposomal daunorubicin in HIV-related Kaposi’s sarcoma, 212

long-term study to evaluate safety and tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis, 94

melanoma detection by oblique-incidence optical spectroscopy, 318

one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis, 688

open label pilot study of Apremilast in rosacea, 313

pediatric longitudinal evaluation on long-term safety of Protopic Ointment for atopic dermatitis, 1217

phase 3 efficacy and study of CD07805/47 topical gel in facial erythema

associated with rosacea, 1216phase 2 trial of erlotinib prior to surgery or

radiation in squamous cell cancer of skin, 207

pilot study of Anakinra in severe atopic dermatitis, 313

PTC299 in HIV-related Kaposi sarcoma, 211randomized double-blind placebo-controlled

clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342

randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis, 1343

randomized study of PH-10 for psoriasis, 315randomized trial of intravenous

immunoglobulin with or without cyclophosphamide in pemphigus, 1077

randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) in hemodialysis and uremic pruritus, 91

safety and efficacy of bimatoprost in women with female pattern hair loss, 936

safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia, 1077

safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis, 95

safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis, 1216

safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis, 313, 687

sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis, 314

sorafenib and temsirolimus in metastatic, recurrent, or unresectable melanoma, 207

spectral diagnosis of cutaneous malignancy, 318

START (Swiss Taxotere Alopecia Prevention Trial), 936

study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma, 209

study of clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis, 92, 314

study of human monoclonal antibody (zanolimumab) to treat mycosis fungoides and Sézary syndrome, 1077

study of LY2439821 in moderate-to-severe psoriasis, 94

study of new drug treatment for acne, 687study of total skin electron beam therapy in

stage IB-IIIA mycosis fungoides, 209study of ultrasonography with elastography in

skin neoplasms, 319study on efficacy and safety of GDC-0449 in

operable basal cell carcinoma, 206study to assess VB-201 in psoriasis, 93, 316study to evaluate safety and effectiveness

of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis, 1487

study to explore efficacy and safety of ASP015K in moderate-to-severe


SU

BJE

CT

IND

EX

psoriasis, 93, 315T cell repertoire analysis of immune mediated

skin diseases, 936topical imiquimod with Nd:YAG laser to tattoo

removal, 1342treatment of actinic keratoses of face with

imiquimod cream followed by photodynamic therapy, 426

treatment of notalgia paresthetica with Xeomin, 91

treatment of surgical scars using pulsed dye laser, 96, 1216

use of etanercept as sole treatment for grade I acute graft versus host disease, 1487

Clobetasol propionatemulti-center open-label study on safety and


open-label study on treatment of mild-to-moderate chronic hand dermatitis with 0.05% emulsion formulation foam, 1398

randomized controlled trial on 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885

safety and efficacy of 0.05% emollient foam in alopecia (CTR), 1077


Cocaine, levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204

Coffeeberryaesthetic benefits of natural ingredients in

skin care, s12 (September)Stiefel/GSK introduces Illumuminesse

Brightening Complex (PP), 938Colchicine

in keloid management (NVR), 549treatment of chronic urticaria with, 1423

Collagen topical gel, Cardium Therapeutics announces FDA 510(k) clearance for Excellagen (PP), 1478

Colorectal cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930

Complement activation by Mycobacterium leprae, 274

Complexion blending, safety and efficacy cosmetic laser treatments in skin of color, 36

Compression bandage and chitosan gel in treatment of venous leg ulcers, 75

Confocal microscopyof cutaneous neoplasms and normal skin

(CTR), 318pilot study using reflectance confocal

microscopy in assessment of novel formulation for melasma, 1260

Contact dermatitisCD70 and Th17 in (BC), 1192phase 2 open-label investigator-initiated study

of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis (RS), 928

Continuing medical educationdemystifying acne algorithms, s5 (June), s24

(June), s26 (June)identifying natural ingredients and their use

in skin care, s4 (September), s21

(September), s22 (September)Contraceptives, oral, advantages of oral

contraceptives and spironolactone for women with acne (DP), 941

Contrast mediaalefacept therapy for nephrogenic systemic

fibrosis associated with (CR), 922fixed drug eruption associated with iohexol

intravenous contrast media (CR), 802

Copper and zinc in natural therapies for hyperpigmentation, s18 (September)

Corrugator supercilii muscle, terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762

Corticosteroidscentral serous chorioretinopathy associated

with topical corticosteroids in psoriasis (CR), 918

FDA approval of Rituxan with corticosteroids for severe vasculitis (PP), 683

multi-center open-label study on safety and efficacy of sequential treatment regimen of clobetasol propionate spray followed by calcitriol ointment in plaque psoriasis, 158

reported adverse effects of isotretinoin and (RR), 287


Cosmetic dermatologyAlma Lasers introduces iPixel fractional

ablative technology (PP), 805assessment of antioxidative capacity kinetics

of cosmetic formulation, 262clinical evidence for activity of



corrugator supercilii muscle terminal nerve ablation using novel thread technique for treatment of hyperdynamic vertical glabellar furrows, 762

cosmeceutical and nutraceutical horizons, 24cosmetic treatments on skin of color, a unique

challenge (editorial), s4 (December)dermal fillers in skin of color population, 494efficacy and tolerability of new monophasic

double-crosslinked hyaluronic acid filler for deep lines and wrinkles, 134

guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673

open-label pilot study on effectiveness and safety of hyaluronic acid in lip augmentation, 145


rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines, 39

Safe Cosmetics Act of 2011 (PP), 1215safety and efficacy of cosmetic laser

treatments for skin of color, 35Cost considerations

increased prevalence of psychiatric disorders

and health care-associated costs in moderate-to-severe psoriasis, 843


CP-690,550for chronic plaque psoriasis (CTR), 316long-term study to evaluate safety and

tolerability in moderate-to-severe chronic plaque psoriasis (CTR), 94

one-year study on efficacy and safety for moderate-to-severe chronic plaque psoriasis (CTR), 688

Cryotherapycompared to imiquimod for actinic keratoses,

lesion clearance, safety, and skin quality outcomes in, 1432

comparison of dimethyl ether and propane to liquid nitrogen in cryosurgical treatment of warts, case report and review of literature on, 1174

imiquimod cream in combination with, in treatment of hypertrophic actinic keratosis (CTR), 426

Cutis laxa, acquired, cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in (RR), 215

Cyclophosphamide, randomized trial of intravenous immunoglobulin with or without cyclophosphamide in pemphigus (CTR), 1077

DDapsone

in dermatitis herpetiformis (CTR), 314randomized study of dapsone gel 5% in

combination with tazarotene cream 0.1% in acne vulgaris, 783


treatment of peristomal pyoderma gangrenosum with topical crushed dapsone (CR), 1059

Dasatinibin locally advanced or metastatic mucosal

melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208

in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207

Daunorubicin, liposomal, in HIV-related Kaposi’s sarcoma (CTR), 212

Depressionassociated with acitretin, 409decrease of insulin growth factor-1 as novel

mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793

Dermabrasion, treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032

Dermacorder, clinical trial on detecting malignant skin lesions with (CTR), 317

Dermal fillersclinical pearls for dermal filler enhancement

in patients with skin of color (DP), s23 (December)

in combined treatment for skin rejuvenation and soft tissue augmentation of aging face, 125


SU

BJE

CT

IND

EX

commentary on rheological evaluation of the physical properties of hyaluronic acid dermal fillers (letter to the editor), 964

cosmeceutical and nutraceutical horizons, 24efficacy and tolerability of new monophasic

double-crosslinked hyaluronic acid filler for deep lines and wrinkles, 134

guide to temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673


rheological evaluation of physical properties of hyaluronic acid dermal fillers, 974


in skin of color population, 494tower technique for injection of hyaluronic

acid fillers in, 1277DermaPACE device for diabetic foot ulcers (PP),

325Dermatitis

atopic. See Atopic dermatitis (AD)CD70 and Th17 in contact dermatitis (BC), 1192dapsone gel 5% for dermatitis herpetiformis

(CTR), 314managing epidermal barrier function in

treatment of dermatoses, s13 (October)

open-label study of safety and efficacy of sertaconazole nitrate in seborrheic dermatitis, 895

open-label study on treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% emulsion formulation foam, 1398


Dermatofibrosarcoma protuberans, malignancy arising with cutaneous tattoo, 837

Dermatology education. See Resident Rounds (RR); Training

Dermatomyositis, fulminant, with flagellate erythema (RR), 902

Dermoscopy, multispectral digital, computer-based analysis in, 21

DermPearls (DP)advantages of oral contraceptives and

spironolactone for women with acne, 941

best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color, s20 (December)

clinical pearls for dermal filler enhancement in patients with skin of color, s23 (December)

diode 810 nm laser as safe, effective modality to meet a growing population need, s8 (December)

fractional laser resurfacing for acne scarring in Fitzpatrick skin types IV–VI, s6 (December)

importance of before and after photographs to practice, 940

laser hair removal in ethnic skin, principles and practical aspects of, s17 (December)

laser hair removal pearls in skin of color, s12

(December)novel 0.65 millisecond pulsed 1064 nm

laser to treat skin of color without skin cooling or anesthetics, s10 (December)

strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with skin of color, s25 (December)

treating lentigines in Asian patients with Q-switched Alexandrite laser, s14 (December)

Devices and equipmentAlma Lasers introduces iPixel fractional

ablative technology (PP), 805clinical trial of Dermacorder for detecting

malignant skin lesions (CTR), 317CoreRx Pharmaceuticals introduces

Xcelodose micro-dosing system (PP), 1478

dermaPACE device for diabetic foot ulcers (PP), 325

Ellman International introduces Pellevé Wrinkle Reduction System to European market (PP), 938

FDA clearance of EndyMed Fractional Skin Resurfacing Applicator (PP), 435

FDA gives provisional approval to MelaFind device (PP), 1340

FDA grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341

FDA panel votes in favor of MelaFind skin cancer detection device (PP), 213

multiple facial burns with new Thermage CPT system (CR), 1320


spectral diagnosis probe in cutaneous malignancy detection (CTR), 318

Syneron devices at 22nd world Congress of Dermatology (PP), 805

Dexpanthenol in atopic dermatitis and other inflammatory skin diseases, s6 (September)

Diabetes mellitus, dermaPACE device for diabetic foot ulcers (PP), 325

Diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80

Dimethyl ether and propane compared to liquid nitrogen in cryosurgical treatment of warts, case report and review of literature on, 1174

Diode laserbest practices and evidence-based use of 800

nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20 (December)

comparison of high-fluence single-pass diode laser to low-fluence multiple-pass diode laser for hair reduction with 18 months of follow up, 62


diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)

Discoid lupus, is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413

Doxycyclinecompared to minocycline for management of

acne (letter to the editor), 965, 966rethinking treatment of acne in severe patient,

s8 (June)self-reported treatment impressions and

satisfaction of papulopustular rosacea patients treated with doxycycline USP 40 mg capsules, 1376

Drug calendar, electronic, in cutaneous drug eruptions, 1430

Drug reactions/toxicitycase of lichen planus following Tdap

vaccination (CR), 1067causes and clinical courses of drug-induced

urticaria, 1019central serous chorioretinopathy associated

with topical corticosteroids in psoriasis (CR), 918

chemical burn from povidone-iodine (CR), 414chloracne-like drug eruption associated with

sorafenib (CR), 1331clinical trial safety and mortality analysis

of etanercept across approved indications, 289

creation of electronic drug calendar in drug hypersensitivity, 1430

cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa (RR), 215

cutaneous reactions to non-steroidal anti-inflammatory drugs, 1160

erythema multiforme-like drug reaction to sorafenib (CR), 1462

fixed drug eruption associated with iohexol intravenous contrast media (CR), 802

iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070

isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204

levamisole-induced retiform purpura (RR), 217metallic taste as side effect of topical

fluorouracil (CR), 1201methemoglobinemia risk from benzocaine

topical products (PP), 684pigmentary changes in patient treatment with

imatinib (CR), 1062Q-switched laser treatment of amiodarone

pigmentation (CR), 1316reported adverse effects of isotretinoin and

systemic corticosteroids (RR), 287short-term and low-dose oral fluconazole

treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360

sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features (CR), 308

tamoxifen-induced hirsutism (CR), 799Drug resistance

antibiotic resistance: an editorial review with recommendations, 724

FDA approves Ceftaroline for MRSA (PP), 104recent advances and future directions in


SU

BJE

CT

IND

EX


Dutasteridein female androgenetic alopecia (NVR), 98versus placebo and finasteride in men with

androgenetic alopecia (CTR), 936Dyschromia, laser treatment with novel 607 nm

pulsed-dye laser, 388

EEastern Virginia Medical School Residency

Programprogram spotlight on (RR), 344ticks of dermatologic significance (RR), 365viral-associated trichodysplasia of

immunosuppression in renal transplant patient (RR), 422

Editorialscancer: this war is personal, 237commentary on rheological evaluation of the

physical properties of hyaluronic acid dermal fillers, 964

cosmetic treatments on skin of color, a unique challenge, s4 (December)

defining the future of dermatology, 15doxycycline versus minocycline for

management of acne, 965, 966introduction to demystifying acne algorithms

supplement, s7 (June)introduction to DermPearls supplement, s4

(December)JDD goes international, 581JDD receives impact factor ranking of 1.954,

1234lessons from an exemplary physician in

private setting, 238new face of fillers: why evidence and

experience both count, 964role of stratum corneum in healthy and

diseased skin, s4 (October)short-term and low-dose oral fluconazole

treatment can cause Stevens-Johnson syndrome in HIV-negative patients, 1360

skin of color: progress made, challenges remain, 459

ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream, 240

why are dermatologists still talking about acne? because so many people have it, and we are always seeking better ways to manage it, 575

Efalizumab, diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80

Elastography, ultrasonic, in skin neoplasms (CTR), 319

Electrocardiography, isotretinoin does not prolong QT intervals and QT dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

Electronic medical records, creation of electronic drug calendar in drug hypersensitivity, 1430

Eletone cream, bilateral comparison study of pimecrolimus cream 1% and medical device cream in atopic dermatitis, 735

Epidermolysis bullosa simplex with mottled pigmentation, novel KRT14 mutation in (CR), 926

Erbium:YAG micropeel treatment, prospective randomized trial on effects of fluence

settings for facial photoaging, 179Erlotinib, phase 2 trial in squamous cell cancer

prior to surgery or radiation (CTR), 207Erythema

erythema multiforme-like drug reaction to sorafenib (CR), 1462

fulminant dermatomyositis with flagellate erythema (RR), 902

phase 3 efficacy and study of CD07805/47 topical gel in facial erythema associated with rosacea (CTR), 1216

thalidomide and complement activation in erythema nodosum leprosum, 274

Erythrasma, case of trichomycosis axillaris and (RR), 1472

Erythromycin in fixed-combination therapy for acne, compared to retinoid monotherapy, 636

Estrogen, advantages of oral contraceptives and spironolactone for women with acne (DP), 941

Etanerceptclinical trial safety and mortality analysis

across approved indications, 289open-label prospective cohort pilot study on

efficacy and safety in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396

retrospective study of racial and ethnic variations in psoriasis treatment with, 866

safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216

as sole treatment for grade I acute graft versus host disease (CTR), 1487


Ethnicity. See Race/ethnicityEtretinate, depression associated with, 409Extensiometry, evaluation of moisturizing effect

of methanolic extract of five medicinal plants incorporated into cream bases using, 1116

Eyelid, modified Tripier flap for lateral eyelid reconstruction (CR), 199

FFacial lipoatrophy, evolution of injectable poly-L-

lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

Facial rejuvenationclinical evidence for activity of




evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

FDA approval for Syneron LED-based skin

rejuvenation system (PP), 435guide to temporal fossa augmentation with

small gel particle hyaluronic acid dermal filler, 673

histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246


safety and efficacy of cosmetic laser treatments for skin of color, 36


Feverfewaesthetic benefits of natural ingredients in

skin care, s12 (September)in atopic dermatitis and other inflammatory

skin diseases, s6 (September)Fibroblasts

complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753


Fibrosis, nephrogenic systemicalefacept therapy for (CR), 922case report and literature review (RR), 622

Finasteridedutasteride versus placebo and finasteride

in men with androgenetic alopecia (CTR), 936

in female androgenetic alopecia (NVR), 98Fitzpatrick skin types

acne in patients with skin of color, s13 (June)fractional laser resurfacing for acne scarring

in Fitzpatrick skin types IV–VI (DP), s6 (December)


ten tips for acne vulgaris treatment in Fitzpatrick skin types IV–VI (BC), 654

Fixed drug eruption associated with iohexol intravenous contrast media (CR), 802

Fluconazole, short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360

Fluocinonideeffects of novel formulation on skin barrier

function in atopic dermatitis, 171efficacy of fluocinonide cream 0.1% in

reducing itch in atopic dermatitis (CTR), 1486

5-Fluorouracilmetallic taste as side effect of (CR), 1201optimal use in keloids (NVR), 548prospective case-based assessment of

sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372

Fluticasone propionate, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103

Follistatin, hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308

Food and Drug AdministrationAbbott withdraws briakinumab from FDA


SU

BJE

CT

IND

EX

review (PP), 435approval of Allergan cell-based assay for

BOTOX (PP), 938approval of Benlysta for lupus erythematosus

(PP), 806approval of Botox for chronic migraine (PP),

104approval of Ceftaroline for MRSA (PP), 104approval of Fibrocell Science LAVIV (PP), 939approval of first generic versions of

levofloxacin (PP), 1076approval of Gardasil to prevent anal cancer

(PP), 325approval of Glenmark Generics mupirocin 2%

ointment (PP), 939approval of imiquimod 5% cream (PP), 683approval of ipilimumab (PP), 552approval of Natroba for head lice (PP), 434approval of Rectiv (nitroglycerin) ointment

(PP), 939approval of Rituxan with corticosteroids for

severe vasculitis (PP), 683approval of Sorilux (calcipotriene) foam (PP),

103approval of Sylatron to treat melanoma (PP),

684approval of Syneron LED-based skin

rejuvenation system (PP), 435approval of Xeomin (incobotulinumtoxinA)

(PP), 1076approval of Zelboraf (vemurafenib) (PP), 1215approval of Zyclara Cream 3.75% for external

genital warts (PP), 552ban on skin whitening products containing

mercury (PP), 1215Cardium Therapeutics announces FDA 510(k)

clearance for Excellagen (PP), 1478clearance of EndyMed Fractional Skin

Resurfacing Applicator (PP), 435clearance of PinPointe FootLaser for nail

fungus (PP), 104Cleure launches FDA-approved broad-

spectrum sunscreen (PP), 1076Fibrocell Science, Inc. and azficel-T (PP), 325Genentech submits New Drug Application to

(PP), 1340Graceway receives FDA approval for Zyclara

Cream 2.5% for actinic keratosis (PP), 1076

grants marketing clearance for HairMax Dual 12 home-use laser phototherapy device (PP), 1341

Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b (PP), 1478

New Drug Application for Yaupon’s mechlorethamine hydrochloride (PP), 1478

new drug applications for vemurafenib in advanced skin cancer (PP), 805

panel votes in favor of MelaFind skin cancer detection device (PP), 213

provisional approval to MelaFind device (PP), 1340

Sagent Pharmaceuticals announces FDA approval of bupivacaine hydrochloride injection (PP), 1478

warning letter to Jaba Labs LLC (PP), 552Foot

clinical evaluation of safety and efficacy of new topical treatment for onychomycosis, 1186


once-daily therapy with sertaconazole nitrate for interdigital tinea pedis, 1135

randomized double-blind vehicle-controlled efficacy and safety study of naftifine 2% cream in tinea pedis, 1282

Fractionated laser therapyfor acne scarring in Fitzpatrick skin types IV–VI

(DP), s6 (December)Alma Lasers introduces iPixel fractional

ablative technology (PP), 805burn scar appearance after fractional carbon

dioxide laser treatment (CTR), 96evaluation of clinical improvement in acne

scars and active acne in 1540-nm non-ablative fractional laser treatment, 907


multiplexed 1,440 and 1,320 nm fractionated laser for chronic photodamage, 1266

nonablative 1927 nm fractional resurfacing for actinic keratoses (PP), 103

Frontalis Activity Measurement Standardcomparing clinical attributes of

abobotulinumtoxinA and onabotulinumtoxinA using, 1148

novel contralateral method for assessing botulinum neurotoxin type-A activity, 968

Frontalis Rating Scaleassessing botulinum neurotoxin type-A

activity with, 968comparing clinical attributes of

abobotulinumtoxinA and onabotulinumtoxinA using, 1148

Fungal infectionsclinical evaluation of safety and efficacy

of new topical treatment for onychomycosis, 1186

double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea cruris, 1142

once-daily therapy with sertaconazole nitrate for interdigital tinea pedis, 1135

randomized double-blind vehicle-controlled efficacy and safety study of naftifine 2% cream in tinea pedis, 1282

role of lasers in onychomycosis (NVR), 1074short-term and low-dose oral fluconazole

treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360

GGabapentin, post-herpetic itch resolved with (CR),

85Gadolinium, alefacept therapy for nephrogenic

systemic fibrosis associated with (CR), 922

Gardasil, FDA approval for prevention of anal cancer (PP), 325

GDC-0449, study on efficacy and safety in operable basal cell carcinoma (CTR), 206

Gelatin sponges in Mohs micrographic surgery defects and staged melanoma excisions, 68

Gemcitabine and pemetrexed disodium in advanced mycosis fungoides or Sézary syndrome (CTR), 210

Geneticsgenes in psoriasis (NVR), 1337recent advances and future directions in


Genital warts, external, FDA approves Zyclara Cream 3.75% for (PP), 552

Glabellar linescomparing clinical attributes of

abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148


FDA approval of Xeomin (incobotulinumtoxinA) for (PP), 1076


Glycolic acidcomparison of 1% tretinoin peeling versus

70% glycolic acid peeling in female patients with melasma, 1439

in Gly-Sal Acne Body Spray (PP), 434Glycyrrhetinic acid-containing barrier repair

cream (BRC-Gly), compared to OTC moisturizer for mild-to-moderate atopic dermatitis in children, 531

Graft versus host disease, acute grade I, use of etanercept as sole treatment for (CTR), 1487

Granuloma annulare, recalcitrant, treatment with adalimumab (CR), 1466

Graves disease, iododerma following radioactive iodine ablation of thyroid for (RR), 1070

Green teaaesthetic benefits of natural ingredients in

skin care, s12 (September)complementary antioxidant function of



Growth factors, decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793

HHair

advances in laser hair removal in skin of color, 1235

approvals, long-term safety data, cancer risk, and treatment options in androgenetic alopecia in women (NVR), 98

case of trichomycosis axillaris and erythrasma (RR), 1472



dutasteride versus placebo and finasteride


SU

BJE

CT

IND

EX

in men with androgenetic alopecia (CTR), 936


hair findings board review (RR), 1464hair regrowth following a Wnt- and follistatin-

containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308

laser hair removal in ethnic skin, principles and practical aspects of (DP), s17 (December)

laser hair removal pearls in skin of color (DP), s12 (December)

novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)

novel treatment of female-pattern androgenetic alopecia with injected bimatoprost 0.03% solution (CR), 795

randomized double-blind placebo-controlled clinical trial on efficacy of abatacept costimulatory blockade in alopecia totalis/universalis, 1342

ROGAINE introduces Unscented Topical Foam (PP), 1076


safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia (CTR), 1077

safety and efficacy of laser hair removal for skin of color, 35




tamoxifen-induced hirsutism (CR), 799Hand

open-label study on treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% emulsion formulation foam, 1398


Harvard Combined Dermatology Residency Training Program

high-yield dermatologic signs in (RR), 197program spotlight on (RR), 186

Head and neck cancerMohs micrographic surgery for cutaneous

lymphadenoma (CR), 1324review of chemopreventative effects of oral

retinoids for, 1292Head lice, FDA approves Natroba for (PP), 434Health care costs

increased prevalence of psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843


Health care outcomes, medication choice and associated health care outcomes and costs in acne and acne-related conditions, 766

Heart


metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900


Hemodialysis, randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) for uremic pruritus in (CTR), 91

Hepatocellular carcinomaclinical clues and patterns in biopsy diagnosis



sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in (CR), 308

Herbal extractsevaluation of moisturizing effect of



Herpes simplex labialis, randomized double-blind placebo-controlled multi-center trial of zinc for (CTR), 1343

Herpes zosterbullous pemphigoid after herpes zoster

vaccine administration (CR), 1328herpes zoster vaccine reduces zoster risk (PP),

324post-herpetic itch resolved with gabapentin

(CR), 85Hidradenitis suppurativa, preliminary results of

treatment with ALA-PDT, 381Hirsutism

comparison of sequential treatment with diode and alexandrite lasers versus alexandrite laser alone in, 1255

safety and efficacy of laser hair removal in, 35tamoxifen-induced (CR), 799

Histiocytosis, intralymphatic, associated with orthopedic implants (RR), 1208

Histology, histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246

HIV infection and AIDSerosive and desquamative syphilis associated

with mucositis in setting of AIDS (RR), 1335

evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

lenalidomide in AIDS-related Kaposi sarcoma (CTR), 210

liposomal daunorubicin in HIV-related Kaposi’s sarcoma (CTR), 212

PTC299 in HIV-related Kaposi sarcoma (CTR), 211

syphilis and lues maligna in, a noduloulcerative disease that still lingers after all these centuries (RR),

1072Hormonal therapy, advantages of oral

contraceptives and spironolactone for women with acne (DP), 941

Hyaluronic acid (HA)bilateral comparison study of pimecrolimus

cream 1% and ceramide-HA emollient foam in atopic dermatitis, 666

commentary on rheological evaluation of the physical properties of HA dermal fillers (letter to the editor), 964

efficacy and tolerability of new monophasic double-crosslinked HA filler for deep lines and wrinkles, 134

efficacy of cream-based novel formulations of HA of different molecular weights in anti-wrinkle treatment, 990

guide to temporal fossa augmentation with small gel particle HA dermal filler, 673

management of impending necrosis associated with soft tissue filler injections (CR), 1007

new face of fillers: why evidence and experience both count (letter to the editor), 964

open-label pilot study on effectiveness and safety in lip augmentation, 145

Restylane for lip augmentation (PP), 684rheological evaluation of physical properties

of HA dermal fillers, 974safety and effectiveness of small and large

gel-particle HA in correction of perioral wrinkles, 982

solid HA tailored to fix fine wrinkles (PP), 1341tower technique for injection of, 1277

Hydrogels, polyacrylamide, characteristics of different products, 1370

Hydroquinone, evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455

Hyperdynamic vertical glabellar furrows, corrugator supercilii muscle terminal nerve ablation using novel thread technique for treatment of, 762

Hyperhidrosis, axillary, same-patient prospective comparison and literature review of Botox versus Dysport for (CR), 1013

Hyperkeratosis of scalp and alopecia in children of color, 511

HyperpigmentationLa Roche-Posay introduces new products

(PP), 938natural therapies for, s11 (September), s15

(September)in nephrogenic systemic fibrosis, case report

and literature review on (RR), 622post-inflammatory, and acne in patients with

skin of color, s13 (June)post-inflammatory, efficacy and safety of

azelaic acid gel 15% in acne and, 586

post-inflammatory, strategies minimizing, in treatment of acne patients with skin of color (DP), s25 (December)

Q-switched laser treatment of amiodarone pigmentation (CR), 1316

Hypersensitivity reactions during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa (RR), 215

Hypomelanosis, progressive macular, 502


SU

BJE

CT

IND

EX

IIbuprofen, cutaneous reactions to non-steroidal

anti-inflammatory drugs, 1160IDP-107, dose-ranging study on safety and efficacy

in acne vulgaris (CTR), 426Imatinib

in mucosal or acral/lentiginous melanoma (CTR), 208

pigmentary changes in patient treatment with (CR), 1062

Imiquimodin combination with cryotherapy in treatment

of hypertrophic actinic keratosis (CTR), 426

compared to cryotherapy in actinic keratoses, lesion clearance, safety, and skin quality outcomes in, 1432

FDA approves Zyclara Cream 3.75% for external genital warts (PP), 552

Graceway receives FDA approval for Zyclara Cream 2.5% for actinic keratosis (PP), 1076

long-term sustained complete clearance of actinic keratoses of face or balding scalp after treatment with, 165

with Nd:YAG laser for tattoo removal (CTR), 1342

optimal use in keloids (NVR), 548regression of internal melanoma metastases

after topical application of (CR), 302review of off-label clinical applications, 1300Taro receives FDA approval for imiquimod 5%

cream (PP), 683treatment of actinic keratosis of face with

imiquimod cream followed by photodynamic therapy (CTR), 426

ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream (letter to the editor), 240

Immune functionautoimmune-mediated blisters (RR), 491CD70 and Th17 involvement in human contact

sensitivity (BC), 1192fatal cutaneous strongyloidiasis as side

effect of mycophenolate mofetil in pemphigus foliaceus in immunocompromised patient (CR), 418

inflammation in rosacea and acne, and implications for patient care, 586


T cell repertoire analysis of immune mediated skin diseases (CTR), 936

Immunoglobulin, intravenous, with or without cyclophosphamide in pemphigus (CTR), 1077

Immunosuppressioncase report of pyoderma gangrenosum

following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545

viral-associated trichodysplasia of, in renal transplant patient (RR), 422

Impact Factor Ranking of JDD (editorial), 1234Impedance measurements, evaluation of

moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using, 1116

IncobotulinumtoxinAFDA approval for glabellar lines (PP), 1076

treatment of notalgia paresthetica with (CTR), 91

Inflammationefficacy and safety of azelaic acid gel


post-inflammatory hyperpigmentation and acne in patients with skin of color, s13 (June)


in rosacea and acne, implications for patient care, 614


Infliximab, review of psoriasis treatment in 120 patients on therapy for a minimum of one year, 539

Insulin growth factor-1, decrease of IGF-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793

Intense pulsed light photorejuvenation, histological and immunohistochemical evaluation of, 1246

Interferonefficacy of vorinostat in combination with

interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403

FDA approves Sylatron to treat melanoma (PP), 684

Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b (PP), 1478

taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659

International alliance of JDD (editorial), 581Intravenous immunoglobulin with or without

cyclophosphamide in pemphigus (CTR), 1077

Iododerma following radioactive iodine ablation of thyroid for Graves disease (RR), 1070

Iohexol, fixed drug eruption associated with intravenous contrast media (CR), 802

Ipilimumab, FDA approval of (PP), 552Irritation of skin from treatment

patient experience and management of dryness and irritation from acne treatment, 605

safety and efficacy of micronized tretinoin 0.05% gel in adolescent acne, 647


in topical rosacea therapy, vehicle formulations affecting, 627

Isotretinoindecrease of insulin growth factor-1 as novel

mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793

depression associated with, 409isotretinoin does not prolong QT intervals


reported adverse effects of systemic corticosteroids and (RR), 287

JJournal of Drugs in Dermatology

international alliance of (editorial), 581receives impact factor ranking of 1.954

(editorial), 1234

KKaposi sarcoma, AIDS and HIV-related

lenalidomide in (CTR), 210liposomal daunorubicin in (CTR), 212PTC299 in (CTR), 211

Keloidsadvances in treatment of, 468new treatments in (NVR), 548

Keratinocytesclinical evidence for activity of


treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032

Keratoacanthoma, eruptive squamous cell carcinomas with keratoacanthoma-like features in patients treated with sorafenib (CR), 308

Kidneysalefacept therapy for nephrogenic systemic

fibrosis (CR), 922chloracne-like drug eruption associated with

sorafenib in metastatic renal cell carcinoma (CR), 1331

clinical clues and patterns in biopsy diagnosis of cutaneous metastases of renal carcinoma (NVR), 678, 930

is chronic cutaneous discoid lupus protective against severe renal disease in systemic lupus erythematosus?, 1413

melanoma in renal transplant patient (RR), 808

nephrogenic systemic fibrosis case report and literature review (RR), 622

randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) for uremic pruritus in renal disease (CTR), 91

viral-associated trichodysplasia of immunosuppression in renal transplant patient (RR), 422

Koebner phenomenon, tattoo sites and psoriasis (CR), 1199

Kojic acid in natural therapies for hyperpigmentation, s17 (September)

KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation (CR), 926

LLanthanum carbonate, evaluation of efficacy in

calciphylaxis (CTR), 1342Laser technology

advances in laser hair removal in skin of color, 1235

Alma Lasers introduces iPixel fractional ablative technology (PP), 805

best practices and evidence-based use of 800 nm diode laser for pseudofolliculitis barbae in skin of color (DP), s20


SU

BJE

CT

IND

EX

(December)burn scar appearance after fractional carbon

dioxide laser treatment (CTR), 96in combined treatment for skin rejuvenation

and soft-tissue augmentation of aging face, 125



confocal scanning laser microscopy, 21diode 810 nm laser as safe, effective modality

to meet a growing population need (DP), s8 (December)

effects of pulsed-dyed laser on scar formation (CTR), 96

evaluation of clinical improvement in acne scars and active acne in 1540-nm non-ablative fractional laser treatment, 907

FDA clearance of PinPointe FootLaser for nail fungus (PP), 104








novel 0.65 millisecond pulsed 1064 nm laser to treat skin of color without skin cooling or anesthetics (DP), s10 (December)

promising future of laser and light therapy, 32prospective randomized trial on effects of

fluence settings in Er:YAG micropeel for facial photoaging, 179

Q-switched laser treatment of amiodarone pigmentation (CR), 1316

role in onychomycosis (NVR), 1074safety and efficacy of cosmetic laser

treatments for skin of color, 35safety of tumescent and laser-assisted

liposuction, review of literature on, 1363

topical imiquimod with Nd:YAG laser for tattoo removal (CTR), 1342

treating lentigines in Asian patients with Q-switched Alexandrite laser (DP), s14 (December)

treatment of dyschromia with novel 607 nm pulsed-dye laser, 388

treatment of surgical scars using pulsed dye laser (CTR), 96, 1216

XTRAC laser for psoriasis (PP), 938Latin Americans, melasma in, 517Lenalidomide

in AIDS-related Kaposi sarcoma (CTR), 210in relapsed mycosis fungoides/Sézary

syndrome (CTR), 209Lentigines, treating lentigines in Asian patients

with Q-switched Alexandrite laser (DP), s14 (December)

Letters to the editorcommentary on rheological evaluation of the

physical properties of hyaluronic acid dermal fillers, 964

doxycycline versus minocycline for management of acne, 965, 966

new face of fillers: why evidence and experience both count, 964

short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients, 1360

ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream, 240

Leukemiaclinical clues and patterns in biopsy diagnosis


dasatinib in unresectable or metastatic squamous cell skin cancer or RAI stage 0-1 chronic lymphocytic leukemia (CTR), 207

Levamisolelevamisole induced necrosis of skin and

neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204

retiform purpura from (RR), 217Levocetirizine, and rupatadine in chronic

idiopathic urticaria, comparative study of efficacy and safety, 1444

Levofloxacin, FDA approves first generic versions of (PP), 1076

Lice, FDA approves Natroba for head lice (PP), 434Lichen planus following Tdap vaccination (CR),

1067Licorice

aesthetic benefits of natural ingredients in skin care, s12 (September)

in atopic dermatitis and other inflammatory skin diseases, s6 (September)

evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116

in natural therapies for hyperpigmentation, s17 (September)

Light emitting diode (LED) systemsFDA approval of Syneron LED-based skin

rejuvenation system (PP), 435self-treatment of mild-to-moderate facial acne

with blue light treatment system, 596

Taenda Luxe device for home treatment of periorbital wrinkles (PP), 1215

Light therapy. See PhototherapyLip


randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis (CTR), 1343

Restylane for lip augmentation (PP), 684treatment of actinic cheilitis by photodynamic

therapy with 5-aminolevulinic acid and blue light activation, 1240

Lipoatrophy, facial, evolution of injectable poly-L-lactic acid from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

Lipolysis, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103

Liposuction, safety of tumescent and laser-assisted liposuction, review of literature on, 1363

Liver cancerclinical clues and patterns in biopsy diagnosis



sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in (CR), 308

Lues malignaerosive and desquamative syphilis associated

with mucositis in setting of AIDS (RR), 1335

a noduloulcerative disease that still lingers after all these centuries (RR), 1072

Lung cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930

Lupus erythematosusFDA approves Benlysta for (PP), 806is chronic cutaneous discoid lupus protective

against severe renal disease in systemic lupus erythematosus?, 1413

manifestations and treatment of (NVR), 1212, 1474

LY2439821 in moderate-to-severe psoriasis (CTR), 94

Lymph nodes, comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207

Lymphadenoma, cutaneous, Mohs micrographic surgery for (CR), 1324

Lymphomaclinical clues and patterns in biopsy diagnosis


diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80

Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213

review of chemopreventative effects of oral retinoids for cutaneous T cell lymphoma, 1292

study evaluating two dose levels of Targretin capsules in refractory cutaneous T-cell lymphoma (CTR), 209

MMallow, evaluation of moisturizing effect of

methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116

Marsh horsetail, evaluation of moisturizing effect of methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116

Matrix scaffolds, xenogeneic, case report of pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and (RR), 545


SU

BJE

CT

IND

EX

Mechlorethamine hydrochloride, New Drug Application for (PP), 1478

Medication choice, and associated health care outcomes and costs in acne and acne-related conditions, 766

Medicinal plantscomparative study of safety and efficacy of


evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116


MelaFind skin cancer detection devicecomparison of diagnostic and biopsy/referral

sensitivity to melanoma between dermatologists and MelaFind (RS), 1078

FDA gives provisional approval to (PP), 1340FDA panel votes in favor of (PP), 213

Melanin synthesis, s16 (September)Melanocytes, treatment of vitiligo with

melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032

Melanomaclinical clues and patterns in biopsy diagnosis

of cutaneous metastases (NVR), 678, 930

comparison of diagnostic and biopsy/referral sensitivity to melanoma between dermatologists and MelaFind (RS), 1078

dasatinib in locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery (CTR), 208

detection by oblique-incidence optical spectroscopy (CTR), 318

early detection and cure in serial screening program, 244

FDA approves Sylatron to treat (PP), 684FDA gives provisional approval to MelaFind

device (PP), 1340FDA panel votes in favor of MelaFind skin

cancer detection device (PP), 213imatinib in mucosal or acral/lentiginous

melanoma (CTR), 208lessons from an exemplary physician in

private setting (editorial), 238new drug applications for vemurafenib in

advanced skin cancer (PP), 805positive results in PLX4032 study (PP), 103regression of internal melanoma metastases

after topical application of imiquimod (CR), 302

in renal transplant patient (RR), 808as second cancer (NVR), 320second cancers after (NVR), 320sorafenib and temsirolimus in metastatic,

recurrent, or unresectable melanoma (CTR), 207

study confirms sunscreen prevents (PP), 213trends in treatment and detection of skin

cancer, 16use of gelatin sponges in Mohs micrographic

surgery and staged melanoma excision, 68

Melanosome transfer, s16 (September)Melasma

comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for, 1025

comparison of 1% tretinoin peeling versus 70% glycolic acid peeling in female patients with, 1439

in Latin Americans, 517pilot study using reflectance confocal

microscopy in assessment of novel formulation for, 1260

Mercury, FDA bans skin whitening products containing (PP), 1215

Merkel cell carcinoma, as banal-appearing aggressive actor (NVR), 811

Metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900

Metallic taste as side effect of topical fluorouracil, 1201

Metastasesbiopsy diagnosis: clinical clues and patterns

to help distinguish cutaneous metastases (NVR), 678, 930


regression of internal melanoma metastases after topical application of imiquimod (CR), 302

Methanolic extract, evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116

Methemoglobinemia risk from benzocaine topical products (PP), 684

Methicillin-resistant Staphylococcus aureus, FDA approves Ceftaroline for (PP), 104

Methyl aminolevulinate (MAL), safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53

Metronidazolein novel rosacea treatment system,

investigator-blind randomized parallel-group study on, 1179

in topical rosacea therapy, vehicle formulations for, 627

Micro-dosing system, CoreRx Pharmaceuticals introduces Xcelodose micro-dosing system (PP), 1478

Migraine, chronic, FDA approves Botox for (PP), 104

Minocyclinein combination treatment for moderate-to-

severe acne (CTR), 90compared to doxycycline for management of

acne (letter to the editor), 965, 966Minoxidil, ROGAINE introduces Unscented Topical

Foam (PP), 1076Mohs micrographic surgery

for cutaneous lymphadenoma (CR), 1324three-dimensional technique as new concept,

1273triage in, 257use of gelatin sponges in, and secondary

wound healing, 68Moisturizers

evaluation of moisturizing effect of methanolic extract of five medicinal plants incorporated into cream bases using impedance and extensiometry methods, 1116

new body moisturizer increases skin hydration and improves AD symptoms in children and adults, 714

in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179

over-the-counter moisturizer compared to prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531

Monoclonal antibodies, study of human monoclonal antibody (zanolimumab) to treat mycosis fungoides and Sézary syndrome (CTR), 1077

Muckle-Wells syndrome, severe, anakinra effective for (PP), 214

Mucositis, erosive, and desquamative syphilis, in setting of AIDS (RR), 1335

Mulberry aesthetic benefits of natural ingredients in

skin care, s11 (September)comparative study of safety and efficacy of


Mupirocin, FDA approval of Glenmark Generics mupirocin 2% ointment (PP), 939

Mycobacterial infectionMycobacterium fortuitum infection following

adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers (CR), 914

thalidomide and complement activation by M. leprae, 274

Mycophenolate mofetil in pemphigus foliaceus, fatal cutaneous strongyloidiasis as side effect of (CR), 418

Mycosis fungoides/Sézary syndromeefficacy of vorinostat in combination with

interferon alpha and extracorporeal photopheresis in late stage of (BC), 403

gemcitabine and pemetrexed disodium in advanced stage of (CTR), 210

lenalidomide in relapse of (CTR), 209new analysis demonstrates activity in

relapsed or refractory transformed mycosis fungoides (PP), 213

study of human monoclonal antibody (zanolimumab) in (CTR), 1077

study of total skin electron beam therapy in stage IB-IIIA mycosis fungoides (CTR), 209


NNaftifine 2% cream

double-blind randomized vehicle-controlled study on efficacy and safety in tinea cruris, 1142

double-blind randomized vehicle-controlled study on efficacy and safety in tinea pedis, 1282

Nail disorders


SU

BJE

CT

IND

EX


FDA clearance of PinPointe FootLaser for onychomycosis (PP), 104

role of lasers in onychomycosis (NVR), 1074Nalfurafine HCl (AC-820), randomized-withdrawal

phase 3 study on safety and efficacy in hemodialysis and uremic pruritus (CTR), 91

Nalmefene, efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853

Nanotechnology, and dermatology education in United States, data from pilot survey, 1037

Nasal basal cell carcinoma, ulcerated nodular, successfully treated with imiquimod 5% cream (letter to the editor), 240

Nasolabial folds and wrinkles, azficel-T in (PP), 325

Natural ingredientsaesthetic benefits of, s10 (September)in atopic dermatitis and other inflammatory

skin diseases, s6 (September)CME: identifying natural ingredients and their

use in skin care, s4 (September), s21 (September), s22 (September)

comparative study of safety and efficacy of 75% mulberry extract oil versus placebo as topical treatment for melasma, 1025

cosmeceutical and nutraceutical horizons, 24defining terms in, s10 (September)evaluation of moisturizing effect of


in hyperpigmentation, s11 (September), s15 (September)


Stiefel/GSK introduces Illumuminesse Brightening Complex (PP), 938

Nd:YAG laser and topical imiquimod for tattoo removal (CTR), 1342

Necrosisgreen tea extract protects human skin

fibroblasts from reactive oxygen species induced necrosis, 1096

levamisole induced necrosis of skin and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204


Neodymium:YAG laser and topical imiquimod for tattoo removal (CTR), 1342Neonates, phototherapy-induced purpura in

transient porphyrinemia of (RR), 306Neoplasia

biopsy diagnosis: clinical clues and patterns to help distinguish cutaneous metastases (NVR), 678, 930

cancer: this war is personal (editorial), 237clinical trial of Dermacorder for detecting

malignant skin lesions (CTR), 317comparison of diagnostic and biopsy/referral

sensitivity to melanoma between dermatologists and MelaFind (RS),

1078comparison of elective lymph node treatment

versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207

confocal microscopy of cutaneous neoplasms and normal skin (CTR), 318



early detection and cure in serial screening for melanoma, 244

FDA approves Gardasil to prevent anal cancer (PP), 325



imatinib in mucosal or acral/lentiginous melanoma (CTR), 208

lenalidomide in AIDS-related Kaposi sarcoma (CTR), 210

lessons from an exemplary physician in private setting (editorial), 238

liposomal daunorubicin in HIV-related Kaposi’s sarcoma (CTR), 212

melanoma detection by oblique-incidence optical spectroscopy (CTR), 318

melanoma in renal transplant patient (RR), 808

melanoma risk after other cancer diagnosis (NVR), 320

Merkel cell carcinoma as banal-appearing aggressive actor (NVR), 811

Mohs micrographic surgery for cutaneous lymphadenoma, 1324


novel devices for diagnosis and treatment, 21phase 2 trial of erlotinib prior to surgery or

radiation in squamous cell cancer of skin (CTR), 207

positive results in PLX4032 melanoma study (PP), 103

PTC299 in HIV-related Kaposi sarcoma (CTR), 211

regression of internal melanoma metastases after topical application of imiquimod (CR), 302

review of chemopreventative effects of oral retinoids for internal neoplasms, 1292

review of off-label clinical applications of imiquimod, 1300

second cancers after melanoma (NVR), 320sorafenib and temsirolimus in metastatic,


sorafenib-induced eruptive squamous cell carcinomas with keratoacanthoma-like features in hepatocellular carcinoma (CR), 308

spectral diagnosis of cutaneous malignancy (CTR), 318

study confirms sunscreen prevents melanoma (PP), 213

study evaluating two dose levels of Targretin

capsules in refractory cutaneous T-cell lymphoma (CTR), 209

study of ultrasonography with elastography in skin neoplasms (CTR), 319

in tattoo site, case of dermatofibrosarcoma protuberans and review of literature, 837

three-dimensional Mohs surgery, a new concept, 1273

trends in treatment and detection of skin cancer, 16

triage in Mohs micrographic surgery, 257ulcerated nodular nasal basal cell carcinoma

successfully treated with imiquimod 5% cream (letter to the editor), 240

use of gelatin sponges in Mohs micrographic surgery and staged melanoma excision, 68

winning poster: predictive factors for severity of scar formation after skin cancer surgeries (RS), 810

Nephrogenic systemic fibrosisalefacept therapy for (CR), 922case report and literature review (RR), 622

Neuroblastoma, review of chemopreventative effects of oral retinoids for, 1292

Neurofibromatosis, eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210

Neurotoxins. See also Botulinum toxincosmeceutical and nutraceutical horizons, 24topical neurotoxin erases crow’s feet (PP),

1341Neutropenia, levamisole induced necrosis of skin

and neutropenia following intranasal cocaine use: a newly recognized syndrome (CR), 1204

News, Views and Reviews (NVR)biopsy diagnosis: clinical clues and patterns

to help distinguish cutaneous metastases, 678, 930

genes in psoriasis in 2011, where are we now?, 1337

manifestations and treatment of cutaneous lupus erythematosus, 1212, 1474

Merkel cell carcinoma as banal-appearing aggressive actor, 811

onychomycosis: is there a role for lasers, 1074second cancers after melanoma and

malignancies with risk for melanoma, 320

what’s new in androgenetic alopecia: approvals, long-term safety data, cancer risk, and treatment options for women, 98

what’s new in keloid treatment: new applications for common therapies, new treatments to come, 548

wound healing: from basic science to clinical practice and beyond, 427

Nitric oxide, taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659

Nitrogen, liquid, compared to dimethyl ether and propane in cryosurgical treatment of warts, case report and review of literature on, 1174

Nitroglycerin, FDA approval for Rectiv (PP), 939Non-steroidal anti-inflammatory agents,

cutaneous reactions to, 1160Notalgia paresthetica treatment with Xeomin

(CTR), 91Nova Southeastern University College of


SU

BJE

CT

IND

EX

Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program


case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545

program spotlight on (RR), 467Nutrition

cosmeceutical and nutraceutical horizons, 24phase 2 double-blind randomized placebo-

controlled trial of novel nutritional supplement product to promote health skin, 1106

randomized placebo-controlled double-blind study on efficacy of citrus bioflavanoid blend in senile purpura, 718

OOatmeal, colloidal, in atopic dermatitis and

other inflammatory skin diseases, s6 (September)

Oblique-incidence optical spectroscopy, melanoma detection by (CTR), 318

Oliveaesthetic benefits of natural ingredients in

skin care, s13 (September)evaluation of moisturizing effect of

methanolic extract incorporated into cream bases using impedance and extensiometry methods, 1116

OnabotulinumtoxinA (ONA)Allergan cell-based assay for BOTOX (PP), 938comparing clinical attributes of

abobotulinumtoxinA and ONA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148

FDA approves Botox for chronic migraine (PP), 104

in moderate-to-severe glabellar lines, rapid onset of response and patient-reported outcomes in, 39

Onychomycosisclinical evaluation of safety and efficacy of

new topical treatment for, 1186FDA clearance of PinPointe FootLaser for

(PP), 104role of lasers in (NVR), 1074

Optical coherence tomography, novel devices for diagnosis and treatment of skin disease, 21

Optical spectroscopy, oblique-incidence, melanoma detection by (CTR), 318

Oregano extract ointment, randomized double-blind petrolatum-controlled study on efficacy in wound healing, 1168

Organic products, use of term, s10 (September)Orthopedic implants, intralymphatic histiocytosis

associated with (RR), 1208Ovarian cancer, clinical clues and patterns

in biopsy diagnosis of cutaneous metastases of (NVR), 678, 930

Oxidative stressassessment of antioxidative capacity kinetics

of topical antioxidants, 262complementary antioxidant function of

caffeine and green tea polyphenols in normal human skin fibroblasts,

753green tea extract protects human skin

fibroblasts from reactive oxygen species induced necrosis, 1096

PPachyonychia congenita, small interfering RNAs

in, 28Pain management

in debridement of leg ulcers (PP), 324FDA approval of Rectiv for pain associated

with anal fissures (PP), 939novel 0.65 millisecond pulsed 1064 nm laser

to treat skin of color without skin cooling or anesthetics (DP), s10 (December)

Pediatric dermatologycomparing Cetaphil Restoraderm System

versus standard skin care in infants with atopic dermatitis (CTR), 1486

comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531

Epiduo pediatric acne study (CTR), 90, 312eruptive plexiform schwannomas in child with

neurofibromatosis I (RR), 1210metabolic syndrome and surrogate markers

of increased cardiovascular risk in children with moderate-to-severe psoriasis compared to age-matched population with warts (BC), 900

new body moisturizer increases skin hydration and improves atopic dermatitis symptoms in children and adults, 714

novel KRT14 mutation in epidermolysis bullosa simplex with mottled pigmentation (CR), 926

pediatric longitudinal evaluation on long-term safety of Protopic Ointment for atopic dermatitis (CTR), 1217

pediatric vascular anomalies (RR), 893rituximab dosing in refractory pemphigus

vulgaris in adolescent male (CR), 202

safety and efficacy of LEO 80185 topical suspension in adolescents with scalp psoriasis (CTR), 95


XTRAC laser for psoriasis (PP), 938Peginterferon alfa-2b, FDA approves Sylatron to

treat melanoma (PP), 684Pemetrexed disodium and gemcitabine in

advanced mycosis fungoides or Sézary syndrome (CTR), 210

Pemphigoid, bullous, after herpes zoster vaccine administration (CR), 1328

Pemphigus foliaceus, fatal cutaneous strongyloidiasis as side effect of mycophenolate mofetil treatment in (CR), 418

Pemphigus vulgarisrandomized trial of intravenous

immunoglobulin with or without cyclophosphamide in (CTR), 1077

refractory, rituximab dosing in adolescent male (CR), 202

Perioral wrinkles, safety and effectiveness of small and large gel-particle hyaluronic acid in correction of, 982

Periorbital wrinkles, Taenda Luxe Device for home treatment of (PP), 1215

PH-10, Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis (PP), 806

Photoagingcomparison of retinol 1.0% and tretinoin

0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217

evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455






Photodynamic therapy (PDT)effect of retinoid pretreatment on outcomes

of PDT for actinic keratosis of hand and forearm, 1124

in onychomycosis (NVR), 1074preliminary results of hidradenitis suppurativa

treatment with ALA-PDT, 381prospective case-based assessment of

sequential therapy with topical fluorouracil cream and ALA-PDT for actinic keratosis, 372

randomized blinded bilateral intraindividual vehicle-controlled trial of PDT with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049


severe cutaneous reaction to PDT with blue light (CR), 1057

treatment of actinic cheilitis by ALA-PDT and blue light activation, 1240

treatment of actinic keratosis of face with imiquimod cream followed by (CTR), 426

trends in treatment of skin cancer, 17Photographs, importance of before and after

photographs to practice (DP), 940Photomedicine board review facts (RR), 750Photopheresis, efficacy of vorinostat in

combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403

Phototherapyadalimumab plus narrowband ultraviolet B

light phototherapy for moderate to severe psoriasis, 366

FDA approval of Syneron LED-based skin rejuvenation system (PP), 435


histological and immunohistochemical evaluation of intense pulsed light photorejuvenation, 1246


SU

BJE

CT

IND

EX

promising future of laser and light therapy, 32randomized blinded bilateral intraindividual

vehicle-controlled trial of photodynamic therapy with 5-aminolevulinic acid and blue light for actinic keratoses of upper extremities, 1049



severe cutaneous reaction to photodynamic therapy with blue light (CR), 1057

Taenda Luxe device for home treatment of periorbital wrinkles (PP), 1215

in transient porphyrinemia of neonate, purpura in (RR), 306

treatment of actinic cheilitis by photodynamic therapy with 5-aminolevulinic acid and blue light activation, 1240

XTRAC laser for psoriasis (PP), 938Pigmentation



effectiveness of topical tacrolimus for vitiligo in skin of color patients, 507

efficacy and safety of azelaic acid gel 15% in post-inflammatory hyperpigmentation and acne, 586

melasma in Latin Americans, 517natural therapies for hyperpigmentation, s11

(September), s15 (September)novel KRT14 mutation in epidermolysis

bullosa simplex with mottled pigmentation (CR), 926

pigmentary changes in patient treatment with imatinib (CR), 1062

pilot study using reflectance confocal microscopy in assessment of novel formulation for melasma, 1260

progressive macular hypomelanosis, 502Q-switched laser treatment of amiodarone

pigmentation (CR), 1316strategies minimizing irritation and iatrogenic

post-inflammatory pigmentation in treating acne patients with skin of color (DP), s25 (December)

topical retinoids for pigmented skin, 483treating lentigines in Asian patients with

Q-switched Alexandrite laser (DP), s14 (December)

treatment of vitiligo with melanocyte-keratinocyte cell suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032

Pimecrolimusbilateral comparison study of pimecrolimus

cream 1% and medical device cream in atopic dermatitis, 735

bilateral comparison study of pimecrolimus cream 1% and medical device emollient foam in atopic dermatitis, 666

Pipeline Previews (PP)Abbott files for 510(k) clearance for vitamin D

assay, 684Abbott withdraws briakinumab from FDA

review (PP), 435Acanya gel acne therapy available in pump,

1479Allergan cell-based assay for BOTOX, 938Alma Lasers introduces iPixel fractional

ablative technology, 805anakinra effective for severe Muckle-Wells

syndrome, 214Cardium Therapeutics announces FDA 510(k)

clearance for Excellagen, 1478Cleure launches FDA-approved broad-

spectrum sunscreen, 1076CoreRx Pharmaceuticals introduces

Xcelodose micro-dosing system, 1478

Crutchfield Dermatology now offers Selphyl wrinkle treatment, 213

Ellman International introduces Pellevé to European market, 938

EndyMed Medical receives FDA clearance for Fractional Skin Resurfacing Applicator, 435

Eucerin launches campaign in Europe and Asia, 1076

FDA approves Benlysta for lupus erythematosus, 806

FDA approves Botox for chronic migraine, 104FDA approves Ceftaroline for MRSA, 104FDA approves Fibrocell Science LAVIV, 939FDA approves first generic versions of

levofloxacin, 1076FDA approves Gardasil to prevent anal cancer,

325FDA approves Glenmark Generics mupirocin

2% ointment, 939FDA approves ipilimumab, 552FDA approves Natroba for head lice, 434FDA approves Rectiv (nitroglycerin) ointment,

939FDA approves Rituxan with corticosteroids for

severe vasculitis, 683FDA approves Sorilux (calcipotriene) foam,

103FDA approves Sylatron to treat melanoma,

684FDA approves Syneron LED-based skin

rejuvenation system, 435FDA approves Xeomin (incobotulinumtoxinA),

1076FDA approves Zyclara Cream 3.75% for

external genital warts, 552FDA bans skin whitening products containing

mercury, 1215FDA clearance of PinPointe FootLaser for nail

fungus, 104FDA gives provisional approval to MelaFind

device, 1340FDA grants clearance for HairMax Dual 12

home-use laser phototherapy device, 1341

FDA panel votes in favor of MelaFind skin cancer detection device, 213

FDA warming letter to Jaba Labs, 552Fibrocell Science, Inc. and azficel-T, 325, 939Genentech submits New Drug Application to

FDA, 1340Gly-Sal Acne Body Spray, 434Graceway receives FDA approval for Zyclara

Cream 2.5% for actinic keratosis, 1076

Helix Biopharma Corp. files clinical hold response on topical interferon alpha-2b, 1478

herpes zoster vaccine reduces zoster risk, 324

injection lipolysis of abdominal subcutaneous fat yields results, 103

La Roche-Posay introduces new products, 938LEO Pharma launches $0 copay program

for Taclonex plaque psoriasis treatments, 683

long-term efficacy and potencies of botulinum toxin A and B, 324

management of pain associated with debridement of leg ulcers, 324

methemoglobinemia risk from benzocaine topical products, 684

new analysis demonstrates activity in relapsed or refractory transformed mycosis fungoides, 213

New Drug Application for vemurafenib in advanced skin cancer, 805

New Drug Application for Yaupon’s mechlorethamine hydrochloride, 1478

nonablative 1927 nm fractional resurfacing for actinic keratoses, 103

positive results in advanced melanoma drug study, 103

Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis, 806

psoriasis drugs not linked to increased heart risks, 1215

Restylane for lip augmentation, 684resveratrol-containing gel for acne, 434ROGAINE introduces Unscented Topical Foam,

1076Safe Cosmetics Act of 2011, 1215Sagent Pharmaceuticals announces

FDA approval of bupivacaine hydrochloride injection, 1478

Sanuwave Health, Inc. dermaPACE device for diabetic foot ulcers, 325

solid hyaluronic acid tailored to fix fine wrinkles, 1341

Stiefel/GSK introduces Illumuminesse Brightening Complex, 938

study confirms sunscreen prevents melanoma, 213

Syneron devices at 22nd World Congress of Dermatology, 805

Taenda Luxe Device for home treatment of periorbital wrinkles, 1215

Taro receives FDA approval for imiquimod 5% cream, 683

topical neurotoxin erases crow’s feet, 1341Topix Pharmaceuticals, Inc. releases Replenix

ResurFIX Skin Barrier Healing Ointment, 805

XTRAC laser for psoriasis, 938Zelboraf (vemurafenib) receives FDA

approval, 1215PLX4032, positive results in melanoma study

(PP), 103Poly-L-lactic acid (PLLA), evolution of injectable

PLLA from correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies, 1001

Polyacrylamide hydrogels, characteristics of different products, 1370

Polyangiitis, microscopic, FDA approval of Rituxan with corticosteroids for (PP), 683

Polyphenols, green teaaesthetic benefits of natural ingredients in

skin care, s12 (September)complementary antioxidant function of

caffeine and green tea polyphenols in normal human skin fibroblasts,


SU

BJE

CT

IND

EX

753Pomegranate, aesthetic benefits of natural

ingredients in skin care, s12 (September)

Porphyrinemia of neonate, transient, phototherapy-induced purpura in (RR), 306

Post-herpetic itch resolved with gabapentin (CR), 85

Post-inflammatory hyperpigmentationand acne in patients with skin of color, s13

(June)efficacy and safety of azelaic acid gel



Povidone-iodine, chemical burn from (CR), 414Pralatrexate in Patients with Relapsed or

Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213

Prevention FDA approves Gardasil to prevent anal cancer

(PP), 325

review of chemopreventative effects of oral retinoids for internal neoplasms, 1292


PROPEL (Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma) (PP), 213

Prurigo nodularis, CC-10004 for (CTR), 91Pruritus

acupressure for pruritus in atopic dermatitis (CTR), 90

CC-10004 for prurigo nodularis (CTR), 91efficacy, safety, and tolerability of topical

nalmefene for pruritus in atopic dermatitis, 853

efficacy of fluocinonide cream 0.1% in reducing itch in atopic dermatitis (CTR), 1486

post-herpetic itch resolved with gabapentin (CR), 85

randomized-withdrawal phase 3 study on safety and efficacy of nalfurafine HCl (AC-820) in hemodialysis and uremic pruritus (CTR), 91

treatment of notalgia paresthetica with Xeomin (CTR), 91

Pseudofolliculitis barbaebest practices and evidence-based use of 800


safety and efficacy of laser hair removal in, 35Psoriasis

Abbott withdraws briakinumab from FDA review (PP), 435

adalimumab plus narrowband ultraviolet B light phototherapy for moderate to severe psoriasis, 366

assessment of national trends in acitretin treatment of, 873

association of depression with acitretin in, 409Bicillin-LA versus placebo for chronic plaque-

type psoriasis unresponsive to topical medications (CTR), 317

central serous chorioretinopathy associated with topical corticosteroids in (CR),

918CP-690-550 ointment for chronic plaque

psoriasis (CTR), 316diffuse large B-cell lymphoma associated with

biologic and other investigational agents in (CR), 80

dose finding study of AEB071 assessing psoriasis area and severity index in plaque psoriasis (CTR), 92

dose-ranging study of AIN457 in moderate-to-severe chronic plaque-type psoriasis (CTR), 93

efficacy and side effects of low-dose acitretin in (CTR), 95

FDA approval of Sorilux (calcipotriene) foam in (PP), 103

frequency of thrombocytopenia in tumor necrosis factor-a inhibitor treatment, 280

genes in (NVR), 1337impact of biologics on disease and treatment

burden of, 189increased prevalence of psychiatric disorders

and health care-associated costs in moderate-to-severe psoriasis, 843

LEO Pharma launches $0 copay program for Taclonex plaque psoriasis treatments (PP), 683

literature review on acitretin in, 772long-term study to evaluate safety and

tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis (CTR), 94



Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers (CR), 914

one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis (CTR), 688

open-label prospective cohort pilot study on efficacy and safety of etanercept in moderate to severe plaque psoriasis in patients without adequate response to adalimumab, 396

Provectus Pharmaceuticals phase 2C clinical trial of PH-10 for psoriasis (PP), 806


randomized controlled trial on clobetasol propionate 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885

randomized study of PH-10 for (CTR), 315retrospective study of racial and ethnic

variations in psoriasis treatment with etanercept, 866

review of chemopreventative effects of oral retinoids for internal neoplasms in, 1292

review of infliximab treatment in 120 patients on therapy for a minimum of one year, 539



salicylic acid 6% in ammonium lactate emollient foam vehicle for scalp psoriasis, 270

study of clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314

study of LY2439821 in moderate-to-severe psoriasis (CTR), 94

study to assess VB-201 in (CTR), 93, 316study to evaluate safety and effectiveness

of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487

study to explore efficacy and safety of ASP015K in moderate-to-severe psoriasis (CTR), 93, 315


tattoo sites and (CR), 1199topical calcipotriene 0.005% and

betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in moderate-to-severe plaque psoriasis, 878

XTRAC laser for (PP), 938Yin-Yang strategy: proposing a new effective

repeatable sequential therapy for, 831

PSORS genes in psoriasis (NVR), 1337Psychiatric disorders, increased prevalence of

psychiatric disorders and health care-associated costs in moderate-to-severe psoriasis, 843

PTC299 in HIV-related Kaposi sarcoma (CTR), 211Pulsed dye laser

effects on scar formation (CTR), 96laser treatment of dyschromia with novel 607

nm pulsed-dye laser, 388treatment of surgical scars using (CTR), 96,

1216Purpura

phototherapy-induced, in transient porphyrinemia of neonate (RR), 306

randomized placebo-controlled double-blind study on efficacy of citrus bioflavanoid blend in senile purpura, 718

retiform, levamisole-induced (RR), 217Pyoderma gangrenosum

following breast reconstructive surgery, case report on treatment with immunosuppression and adjunctive xenogeneic matrix scaffolds (RR), 545

treatment with topical crushed dapsone (CR), 1059

QQ-switched laser treatment

of amiodarone pigmentation (CR), 1316treating lentigines in Asian patients with


QT intervals and QT dispersion, isotretinoin does not prolong QT intervals and QT


SU

BJE

CT

IND

EX

dispersion in severe acne: a surprising finding for a drug with numerous side effects, 710

RRace/ethnicity

acne in patients with skin of color, s13 (June)advances in laser hair removal in skin of

color, 1235advances in treatment of keloids, 468best practices and evidence-based use of 800


clinical pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)

community-based study of skin conditions and concerns in South Asian Americans (BC), 524

cosmetic treatments on skin of color, a unique challenge (editorial), s4 (December)

dermal fillers in skin of color, 494diode 810 nm laser as safe, effective modality


effectiveness of topical tacrolimus for vitiligo in skin of color, 507





melasma in Latin Americans, 517novel 0.65 millisecond pulsed 1064 nm laser


progressive macular hypomelanosis, 502retrospective study of racial and ethnic






topical retinoids for pigmented skin, 483treating lentigines in Asian patients with


Radiation therapyelectronic brachytherapy for non-melanoma

skin cancer treatment (CTR), 206phase 2 trial of erlotinib prior to surgery or

radiation in squamous cell cancer (CTR), 207

study of total skin electron beam therapy in stage IB-IIIA mycosis fungoides (CTR), 209

Radiofrequency device, multiple facial burns with new Thermage CPT system (CR), 1320

Radioiodine ablation of thyroid, iododerma

following (RR), 1070Rapamycin, recent advances and future directions

in medical management of skin disease, 28

RAW 264.7 cells, taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659

Reactive oxygen speciesassessment of kinetics of antioxidative

capacity of topical antioxidants, 262complementary antioxidant function of



Reconstructive surgerycase report of pyoderma gangrenosum


modified Tripier flap for lateral eyelid reconstruction (CR), 199

Red light source, safety and efficacy comparison of blue versus red light sources for MAL-PDT in photodamaged skin, 53

Reflectance confocal microscopy (RCM), pilot study using RCM in assessment of novel formulation for melasma, 1260

REGN668, sequential ascending dose study on safety and tolerability in atopic dermatitis (CTR), 314

Renal conditions. See KidneysResident Rounds (RR)

Albert Einsten College of Medicine Unified Division of Dermatology Residency Program program spotlight, 1122

autoimmune-mediated blisters (for the Boards), 491

case of trichomycosis axillaris and erythrasma, 1472

case report on pyoderma gangrenosum following breast reconstructive surgery treated with immunosuppression and adjunctive xenogeneic matrix scaffolds, 545

cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa, 215

dermal melanoma in transplant patient, 808Eastern Virginia Medical School Dermatology

Residency Program program spotlight, 344

erosive and desquamative syphilis associated with mucositis in setting of AIDS, 1335

eruptive plexiform schwannomas in child with neurofibromatosis I, 1210

fulminant dermatomyositis with flagellate erythema, 902

hair findings board review, 1464Harvard Combined Dermatology Residency

Training Program program spotlight, 186

high-yield dermatologic signs in Harvard Combined Residency Training Program, 197

highlights of common autoimmune connective tissue diseases, 1314

integrated basic and clinical sciences

conference, 1045intralymphatic histiocytosis associated with

orthopedic implants, 1208iododerma following radioactive iodine

ablation of thyroid for Graves disease, 1070

levamisole-induced retiform purpura, 217nephrogenic systemic fibrosis: case report

and literature review, 622noduloulcerative disease that still lingers after

all these centuries, 1072Nova Southeastern University College

of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program program spotlight, 467

pediatric vascular anomalies, 893photomedicine board review facts, 750phototherapy-induced purpura in transient

porphyrinemia of neonate, 306reported adverse effects of isotretinoin and

systemic corticosteroids, 287sound-alike and look-alike terms in

dermatology, 1196study aid: diagnosis and associations, 611ticks of dermatologic significance, 365University of California Davis Department of

Dermatology Residency Training Program program spotlight, 253

University of California Irvine Department of Dermatology Residency Training Program program spotlight, 593

University of California San Francisco Department of Dermatology Residency Training Program program spotlight, 883

University of Connecticut Dermatology Residency program spotlight, 1452

University of Louisville Dermatology Residency Training Program program spotlight, 1289

University of Massachusetts Medical School Dermatology Residency Program program spotlight, 716

University of Texas Southwestern Medical Center Dermatology Residency Program program spotlight, 1016

viral-associated trichodysplasia of immunosuppression in renal transplant patient, 422

Resident Spotlight (RS)comparison of diagnostic and biopsy/referral

sensitivity to melanoma between dermatologists and MelaFind, 1078

winning poster: phase 2 open-label investigator-initiated study of safety and efficacy of apremilast in recalcitrant contact or atopic dermatitis, 928

winning poster: predictive factors for severity of scar formation after skin cancer surgeries, 810

Resveratrol-containing gel for acne (PP), 434Retinoids

adapalene gel 0.3% in atrophic acne scars (CTR), 96

assessment of national trends in acitretin treatment of psoriasis, 873

in combination treatment for moderate-to-severe acne (CTR), 90


comparison of retinol 1.0% and tretinoin


SU

BJE

CT

IND

EX

0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217

decrease of insulin growth factor-1 as novel mechanism for anti-androgen effect of isotretinoin and its association with depression (BC), 793

and depression, 409effect of retinoid pretreatment on outcomes

of photodynamic therapy for actinic keratosis of hand and forearm, 1124

Epiduo pediatric acne study (CTR), 90, 312isotretinoin does not prolong QT intervals


literature review on acitretin in dermatology, 772

randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783

reported adverse effects of systemic corticosteroids and isotretinoin (RR), 287


review of chemopreventative effects for internal neoplasms, 1292



topical, for pigmented skin, 483in topical fixed-combination therapy and

topical monotherapy in acne, evidence-based review on, 636

Retinol, comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217

Retinopathy, central serous chorioretinopathy associated with topical corticosteroids in psoriasis (CR), 918

Rheological evaluation of physical properties of hyaluronic acid dermal fillers, 974

commentary on (letter to the editor), 964Rhytids (rhytides). See WrinklesRituximab

dosing in refractory pemphigus vulgaris in adolescent male (CR), 202

FDA approval of Rituxan with corticosteroids for severe vasculitis (PP), 683

RNA, small interfering, in pachyonychia congenita, 28

Rosaceainflammation in rosacea and acne,

implications for patient care, 614investigator-blind randomized parallel-group

study on efficacy of novel rosacea treatment system, 1179

open label pilot study of Apremilast in (CTR), 313

papulopustular, self-reported treatment impressions and satisfaction of patients treated with doxycycline USP 40 mg capsules for, 1376


vehicle formulations affecting efficacy, tolerability, and compliance with topical therapy, 627

Rose bengal, randomized study of PH-10 for psoriasis (CTR), 315

RT001, topical neurotoxin erases crow’s feet (PP), 1341

Rupatadine and levocetirizine in chronic idiopathic urticaria, comparative study of efficacy and safety, 1444

SSafe Cosmetics Act of 2011 (PP), 1215Safety issues

in blue versus red light sources for MAL-PDT in photodamaged skin, 53

in calcium hydroxylapatite rejuvenation of aging hand, 52-week study of, 47


clinical trial safety and mortality analysis of etanercept across approved indications, 289

comparative study of efficacy and safety of rupatadine and levocetirizine in chronic idiopathic urticaria, 1444


in comparison of cryotherapy and imiquimod for actinic keratoses, 1432

in cosmetic laser treatments for skin of color, 35

in dermal fillers in skin of color population, 494

diffuse large B-cell lymphoma associated with biologic and other investigational agents in psoriasis (CR), 80

diode 810 nm laser as safe, effective modality to meet a growing population need (DP), s8 (December)

dose-ranging study on safety and efficacy of IDP-107 in acne vulgaris (CTR), 426

double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea cruris, 1142

double-blind randomized vehicle-controlled study on efficacy and safety of naftifine 2% cream in tinea pedis, 1282

efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853

efficacy and safety of different concentrations of ZK245186 in atopic dermatitis (CTR), 313

hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308


in LEO 80185 topical suspension for adolescents with scalp psoriasis (CTR), 95

long-term study to evaluate safety and tolerability of CP-690,550 in moderate-to-severe chronic plaque psoriasis (CTR), 94


one-year study on efficacy and safety of CP-690,550 for moderate-to-severe chronic plaque psoriasis (CTR), 688



open-label study of safety and efficacy of sertaconazole nitrate in seborrheic dermatitis, 895



safety and effectiveness of small and large gel-particle hyaluronic acid in correction of perioral wrinkles, 982


safety and efficacy of clobetasol propionate 0.05% emollient foam in alopecia (CTR), 1077




safety of tumescent and laser-assisted liposuction, review of literature on, 1363

safety study of AMG 157 in healthy subjects and subjects with atopic dermatitis (CTR), 313, 687

sequential ascending dose study on safety and tolerability of REGN668 in atopic dermatitis (CTR), 314

study on clinical activity, safety, and tolerability of SRT2104 in moderate-to-severe plaque-type psoriasis (CTR), 92, 314

study on efficacy and safety of GDC-0449 in operable basal cell carcinoma (CTR), 206

study to evaluate safety and effectiveness of oral apremilast (CC-10004) in moderate-to-severe plaque psoriasis (CTR), 1487

study to explore efficacy and safety of ASP015K in moderate-to-severe psoriasis (CTR), 93, 315

Salicylic acidin ammonium lactate emollient foam vehicle

for scalp psoriasis, 270in Gly-Sal Acne Body Spray (PP), 434

Salmeterol xinafoate, injection lipolysis of abdominal subcutaneous fat yields results (PP), 103

Sarcoma, AIDS and HIV-related Kaposi sarcomalenalidomide in (CTR), 210liposomal daunorubicin in (CTR), 212PTC299 in (CTR), 211


SU

BJE

CT

IND

EX

Scalp cooling in prevention of chemotherapy-induced alopecia (CTR), 936

Scalp lesionslong-term complete sustained clearance of

actinic keratoses of face or balding scalp after imiquimod treatment, 95

randomized controlled trial on clobetasol propionate 0.05% spray for moderate-to-severe plaque psoriasis of scalp, 885


salicylic acid 6% in ammonium lactate emollient foam vehicle for scalp psoriasis, 270


Scars/scarringadapalene gel in treatment of atrophic acne

scars (CTR), 96burn scar appearance after fractional carbon

dioxide laser treatment (CTR), 96effects of pulsed-dyed laser on scar formation

(CTR), 96evaluation of clinical improvement in acne

scars and active acne in 1540-nm non-ablative fractional laser treatment, 907



treatment of surgical scars using pulsed dye laser (CTR), 96, 1216


Schwannoma, eruptive plexiform, in child with neurofibromatosis I (RR), 1210

Screening, early detection and cure of melanoma in serial screening, 244

Seborrheic dermatitis, open-label study of safety and efficacy of sertaconazole nitrate in, 895

Secukinumab, safety and efficacy of secukinumab compared to etanercept in moderate-to-severe chronic plaque-type psoriasis (CTR), 1216

Serotonin reuptake inhibitor therapy, selective, cutaneous hypersensitivity to resulting in acquired cutis laxa (RR), 215

Sertaconazole nitrateopen-label study of safety and efficacy in

seborrheic dermatitis, 895treatment of interdigital tinea pedis with

once-daily therapy with, 1135Sézary syndrome. See Mycosis fungoides/Sézary

syndromeSkin barrier function

clinical relevance of maintaining structural and functional integrity of stratum corneum, s5 (October)

comparison of OTC moisturizer and prescription barrier creams in mild-to-moderate atopic dermatitis of children, 531

effects of novel fluocinonide cream formulation on, in atopic dermatitis, 171

managing epidermal barrier function in treatment of dermatoses, s13

(October)new body moisturizer increases skin

hydration and improves atopic dermatitis symptoms in children and adults, 744

role of stratum corneum in healthy and diseased skin (editorial), s4 (October)

Topix Pharmaceuticals, Inc. releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805

Skin cancercancer: this war is personal (editorial), 237clinical trial of Dermacorder for detecting

malignant skin lesions (CTR), 317comparison of diagnostic and biopsy/referral

sensitivity to melanoma between dermatologists and MelaFind (RS), 1078

comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk squamous cell carcinoma (CTR), 207

confocal microscopy of cutaneous neoplasms and normal skin (CTR), 318



dermal melanoma in renal transplant patient (RR), 808

early detection and cure in serial screening for melanoma, 244

electronic brachytherapy for non-melanoma skin cancer treatment (CTR), 206

eruptive squamous cell carcinoma with keratoacanthoma-like features in sorafenib treatment (CR), 308



imatinib in mucosal or acral/lentiginous melanoma (CTR), 208

lessons from an exemplary physician in private setting (editorial), 238

Merkel cell carcinoma as banal-appearing aggressive actor (NVR), 811

Mohs micrographic surgery for cutaneous lymphadenoma (CR), 1324


novel devices for diagnosis and treatment, 21phase 2 trial of erlotinib prior to surgery or

radiation in (CTR), 207sorafenib and temsirolimus in metastatic,


spectral diagnosis of cutaneous malignancy (CTR), 318


study of ultrasonography with elastography in skin neoplasms (CTR), 319

study on efficacy and safety of GDC-0449 in operable basal cell carcinoma (CTR), 206

three-dimensional Mohs surgery, a new concept, 1273

trends in treatment and detection of, 16triage in Mohs micrographic surgery, 257ulcerated nodular nasal basal cell carcinoma


unresectable or metastatic, dasatinib in (CTR), 207

use of gelatin sponges in Mohs micrographic surgery and staged melanoma excision, 68


Skin Health Experimental Product (SHEP), phase 2 double-blind randomized placebo-controlled trial of novel nutritional supplement product to promote healthy skin, 1106

Skin lightening productsFDA ban on skin whitening products

containing mercury (PP), 1215natural therapies for hyperpigmentation, s11

(September), s15 (September)Skin of color

acne in patients with, s13 (June)advances in laser hair removal in, 1235advances in treatment of keloids, 468best practices and evidence-based use of 800


clinical pearls for dermal filler enhancement in patients with skin of color (DP), s23 (December)

community-based study of skin conditions and concerns in South Asian Americans (BC), 524

cosmetic treatments on skin of color, a unique challenge (editorial), s4 (December)

dermal fillers in, 494diode 810 nm laser as safe, effective modality


effectiveness of topical tacrolimus for vitiligo in, 507





melasma in Latin Americans, 517novel 0.65 millisecond pulsed 1064 nm laser


progress made, challenges remain (editorial), 459

progressive macular hypomelanosis, 502retrospective study of racial and ethnic


safety and efficacy of cosmetic laser treatments for, 35


strategies minimizing irritation and iatrogenic post-inflammatory pigmentation in treating acne patients with (DP), s25 (December)


SU

BJE

CT

IND

EX


topical retinoids for pigmented skin, 483Skin resurfacing

EndyMed Medical receives FDA clearance for Fractional Skin Resurfacing Applicator (PP), 435



Sodium sulfacetamide-sulfur in topical rosacea therapy, vehicle formulations for, 627

Sodium thiosulfate, topical sodium thiosulfate 25% treatment for ulcerative calcinosis cutis, 1042

Soft tissue augmentationcombined treatment for skin rejuvenation and

soft-tissue augmentation of aging face, 125


Sorafenibchloracne-like drug eruption associated with

(CR), 1331eruptive squamous cell carcinomas with

keratoacanthoma-like features in patients treated with (CR), 308

erythema multiforme-like drug reaction to (CR), 1462

and temsirolimus in metastatic, recurrent, or unresectable melanoma (CTR), 207

Sound-line and look-alike terms in dermatology (RR), 1196

South Asian Americans, community-based study of skin conditions and concerns in (BC), 524

Soy productsaesthetic benefits of natural ingredients in

skin care, s11 (September)for hyperpigmentation, s16 (September)

Spectral diagnosis of cutaneous malignancy (CTR), 318

Spinosad, FDA approves Natroba for head lice (PP), 434

Spironolactoneadvantages of oral contraceptives and

spironolactone for women with acne (DP), 941

in female androgenetic alopecia (NVR), 100Squamous cell carcinoma (SCC)

comparison of elective lymph node treatment versus clinical observation in absence of palpable lymph nodes in high risk SCC (CTR), 207


electronic brachytherapy for treatment of (CTR), 206

eruptive, with keratoacanthoma-like features in sorafenib treatment (CR), 308

phase 2 trial of erlotinib prior to surgery or radiation in (CTR), 207

SRD174 cream, efficacy, safety, and tolerability of SRD174 cream for pruritus in atopic dermatitis, 853

SRT2104, study of clinical activity, safety, and tolerability in moderate-to-severe plaque-type psoriasis (CTR), 92, 314

Staphylococcus aureus, FDA approves Ceftaroline for MRSA (PP), 104


Stevens-Johnson syndrome, short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients (letter to the editor), 1360

Stoma site, treatment of peristomal pyoderma gangrenosum with topical crushed dapsone (CR), 1059

Stomach cancer, clinical clues and patterns in biopsy diagnosis of cutaneous metastases (NVR), 678, 930

Stratum corneumclinical relevance of maintaining structural

and functional integrity of, s5 (October)

managing epidermal barrier function in treatment of dermatoses, s13 (October)

role in healthy and diseased skin (editorial), s4 (October)

Striae, multi-center clinical study and review of fractional ablative carbon dioxide laser resurfacing for rhytides, photoaging, scars, and striae, 352

Strongyloidiasis, fatal cutaneous, as side effect of mycophenolate mofetil in pemphigus foliaceus (CR), 418

SunscreensCleure launches FDA-approved broad-

spectrum sunscreen (PP), 1076impact of natural sunlight exposure on UVB-

SPF and UVA-PF of UVA/UVB SPF 50 sunscreen, 150

in novel rosacea treatment system, investigator-blind randomized parallel-group study on, 1179


Swiss Taxotere Alopecia Prevention Trial (START) (CTR), 936

Syphiliserosive and desquamative, associated with

mucositis in setting of AIDS (RR), 1335

and lues maligna in HIV infection (RR), 1072

TT cell(s)

CD70 and Th17 involvement in human contact sensitivity (BC), 1192

repertoire analysis of immune mediated skin diseases (CTR), 936

T cell leukemia/lymphoma, adult (ATLL), vesiculobullous variant in Caribbean émigré (CR), 1469

T cell lymphomaPralatrexate in Patients with Relapsed

or Refractory Peripheral T-Cell Lymphoma (PROPEL) (PP), 213

review of chemopreventative effects of oral retinoids for cutaneous T cell lymphoma, 1292

study evaluating two dose levels of Targretin capsules in refractory cutaneous T cell lymphoma (CTR), 209

Tacrolimus, topical, effectiveness for vitiligo in skin of color, 507

Tamoxifen-induced hirsutism (CR), 799Tattoos

malignancy arising within, case of dermatofibrosarcoma protuberans and review of literature, 837

and psoriasis (CR), 1199topical imiquimod with Nd:YAG laser for

removal of (CTR), 1342Taurine chloramine inhibits NO and TNF-a

production in zymosan plus interferon-g activated RAW 264.7 cells, 659

Tazaroteneeffect of retinoid pretreatment on outcomes

of photodynamic therapy for actinic keratosis of hand and forearm, 1124

randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in acne vulgaris, 783


Temporal fossa augmentation with small gel particle hyaluronic acid dermal filler, 673

Temsirolimus and sorafenib in metastatic, recurrent, or unresectable melanoma (CTR), 207

Tetanus, diphtheria and pertussis vaccination, case of lichen planus following (CR), 1067

Tetrahydroxypropyl ethylenediamine (THPE), clinical evidence for activity of THPE as new anti-aging active cosmetic, 1102

Thalidomide, and complement activation by Mycobacterium leprae, 274

Thermage CPT system, multiple facial burns with (CR), 1320

Thrombocytopenia in tumor necrosis factor-a inhibitor therapy for psoriasis, frequency of, 280

Thyroidclinical clues and patterns in biopsy diagnosis

of cutaneous metastases of thyroid cancer (NVR), 678, 930


Ticks of dermatologic significance (RR), 365Tinea cruris, double-blind randomized vehicle-

controlled study on efficacy and safety of naftifine 2% cream in, 1142

Tinea pedisonce-daily therapy with sertaconazole nitrate

for, 1135randomized double-blind vehicle-controlled

efficacy and safety study of naftifine 2% cream in, 1282

Total skin electron beam therapy (TSEBT) in stage IB-IIIA mycosis fungoides (CTR), 209

Tower technique for injection of hyaluronic acid fillers, 1277

TrainingAlbert Einsten College of Medicine Unified

Division of Dermatology Residency Program (RR), 1122, 1196, 1208


CME: demystifying acne algorithms, s5 (June), s24 (June), s26 (June)

CME: identifying natural ingredients and their use in skin care, s4 (September), s21 (September), s22 (September)

Eastern Virginia Medical School Dermatology Residency Program (RR), 344, 365, 422

hair findings board review (RR), 1464Harvard Combined Dermatology Residency

Training Program (RR), 186, 197high yield dermatologic signs (RR), 197highlights of common autoimmune


SU

BJE

CT

IND

EX

connective tissue diseases (RR), 1314

integrated basic and clinical sciences conference (RR), 1045

nanotechnology and dermatology education in United States, data from pilot survey, 1037

Nova Southeastern University College of Osteopathic Medicine and Broward General Medical Center Dermatology Residency Training Program (RR), 467, 491, 545

pediatric vascular anomalies (RR), 893photomedicine board review facts (RR), 750sound-alike and look-alike terms in

dermatology (RR), 1196study aid: diagnosis and associations (RR),

611University of California Davis Department of

Dermatology Residency Training Program (RR), 253, 287, 306

University of California Irvine Department of Dermatology Residency Training Program (RR), 593, 611, 622

University of California San Francisco Department of Dermatology Residency Training Program (RR), 883, 893, 902

University of Connecticut School of Medicine Dermatology Residency (RR), 1452, 1464, 1472

University of Louisville School of Medicine Dermatology Residency Training Program (RR), 1289, 1314, 1335

University of Massachusetts Medical School Dermatology Residency Program (RR), 716, 750, 808

University of Texas Southwestern Medical Center Dermatology Residency Program (RR), 1016, 1045, 1070, 1072

Transepidermal water losseffects of novel fluocinonide cream

formulation on skin barrier function in atopic dermatitis, 171

new body moisturizer increases skin hydration and improves atopic dermatitis symptoms in children and adults, 744

Transplant recipientsmelanoma in renal transplant patient (RR),

808viral-associated trichodysplasia of

immunosuppression in renal transplant patient (RR), 422

Tretinoinin combination treatment for moderate-to-

severe acne (CTR), 90comparison of 1% tretinoin peeling versus

70% glycolic acid peeling in female patients with melasma, 1439

comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217



Triage in Mohs micrographic surgery, 257Trichodysplasia of immunosuppression, viral-

associated, in renal transplant patient (RR), 422

Trichomycosis axillaris, and erythrasma, case of (RR), 1472

Tripier flap, modified, for lateral eyelid reconstruction (CR), 199

Triple compression bandage and chitosan gel in treatment of venous leg ulcers, 75

Tumeric, aesthetic benefits of natural ingredients in skin care, s12 (September)

Tumescent liposuction, safety of tumescent and laser-assisted liposuction, review of literature on, 1363

Tumor necrosis factor-aadalimumab plus narrowband ultraviolet B

light phototherapy for moderate to severe psoriasis, 366

clinical trial safety and mortality analysis in patients receiving etanercept across approved indications, 289

etanercept as sole treatment for grade I acute graft versus host disease (CTR), 1487

frequency of thrombocytopenia in psoriasis treated with tumor necrosis factor-a inhibitors, 280

Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers (CR), 914


retrospective study of racial and ethnic variations in psoriasis treatment with etanercept, 866

review of infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year, 539


taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659


treatment of recalcitrant generalized granuloma annulare with adalimumab (CR), 1466

Tyrosinase, asethetic benefits of natural ingredients in skin care, s11 (September)

Tyrosinase inhibitors, asethetic benefits of natural ingredients in skin care, s11 (September)

UUlcers


novel treatment for ulcerative calcinosis cutis, 1042

pain management in debridement of leg ulcers (PP), 324

Topix Pharmaceuticals releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805

treatment efficacy of triple bandage compression and chitosan gel in

venous leg ulcers, 75ulcerated nodular nasal basal cell carcinoma


Ultrasonography with elastography in skin neoplasms (CTR), 319

Ultraviolet (UV) radiation exposureadalimumab plus narrowband UV B light

phototherapy for moderate to severe psoriasis, 366

assessment of antioxidative capacity kinetics of topical antioxidants in, 262

Cleure launches FDA-approved broad-spectrum sunscreen (PP), 1076

complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753

evaluation of prescription strength 4% hydroquinone/10% L-ascorbic acid treatment system for photodamage in normal to oily skin, 1455

impact on UVB-SPF and UVA-PF of UVA/UVB SPF 50 sunscreen, 150

in keloids (NVR), 550multiplexed 1,440 and 1,320 nm fractionated

laser for chronic photodamage, 1266

Unified Division of Dermatology of Albert Einstein College of Medicine

eruptive plexiform schwannomas in child with neurofibromatosis I (RR), 1210

intralymphatic histiocytosis associated with orthopedic implants (RR), 1208

program spotlight on Residency Program (RR), 1122

sound-alike and look-alike terms in dermatology (RR), 1196

University of California–Davisphototherapy-induced purpura in transient

porphyrinemia of neonate (RR), 306program spotlight on Department of

Dermatology Residency Training Program (RR), 253

reported adverse effects of isotretinoin and systemic corticosteroids (RR), 287

University of California–Irvinenephrogenic systemic fibrosis: case report

and literature review (RR), 622program spotlight on Dermatology Residency

Training Program (RR), 593study aid: diagnosis and associations (RR),

611University of California–San Francisco

fulminant dermatomyositis with flagellate erythema (RR), 902

pediatric vascular anomalies (RR), 893program spotlight on Department of

Dermatology Residency Training Program (RR), 883

University of Connecticut School of Medicinecase of trichomycosis axillaris and erythrasma

(RR), 1472hair findings board review (RR), 1464program spotlight on Dermatology Residency

(RR), 1452University of Louisville School of Medicine

erosive and desquamative syphilis associated with mucositis in setting of AIDS (RR), 1335

highlights of common autoimmune connective tissue diseases (RR), 1314

program spotlight on Dermatology Residency


SU

BJE

CT

IND

EX

Training Program (RR), 1289University of Massachusetts Medical School

dermal melanoma in transplant patient (RR), 808

photomedicine board review facts (RR), 750program spotlight on Dermatology Residency

Program (RR), 716University of Texas Southwestern Medical Center

integrated basic and clinical sciences conference (RR), 1045


noduloulcerative disease that still lingers after all these centuries (RR), 1072

program spotlight on Dermatology Residency Program (RR), 1016

Urticariachronic, treatment with colchicine, 1423chronic idiopathic, comparative study of

efficacy and safety of rupatadine and levocetirizine in, 1444

drug-induced, causes and clinical courses of, 1019

VVaccines

bullous pemphigoid after herpes zoster vaccine administration (CR), 1328

case of lichen planus following Tdap vaccination (CR), 1067

FDA approves Gardasil to prevent anal cancer (PP), 325

herpes zoster vaccine reduces zoster risk (PP), 324

Vascular anomalies, pediatric (RR), 893Vasculitis, FDA approval of Rituxan with

corticosteroids for (PP), 683VB-201, study to assess in psoriasis (CTR), 93, 316Vehicle formulations

in topical acne therapy, importance of, s17 (June)

in topical rosacea therapy, affecting efficacy, tolerability, and compliance, 627

Vemurafenibnew drug applications for vemurafenib in

advanced skin cancer (PP), 805Zelboraf receives FDA approval (PP), 1215

Venous leg ulcers, treatment efficacy of triple bandage compression and chitosan gel in, 75

Vismodegib, Genentech submits New Drug Application to FDA (PP), 1340

Vitamin DAbbott files for 510(k) clearance for vitamin D

assay (PP), 684in keloids (NVR), 550multi-center open-label study on safety and


Vitiligo vulgarisin skin of color, effectiveness of topical

tacrolimus treatment in, 507treatment with melanocyte-keratinocyte cell

suspension versus dermabrasion only in pilot study with 12-month follow-up, 1032

Vorinostat, efficacy in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome (BC), 403

WWarts

comparison of dimethyl ether and propane to liquid nitrogen in cryosurgical treatment of, case report and review of literature on, 1174

FDA approves Zyclara Cream 3.75% for external genital warts (PP), 552


Wegener’s granulomatosis, FDA approval of Rituxan with corticosteroids for (PP), 683

Wnt, hair regrowth following a Wnt- and follistatin-containing treatment, safety and efficacy in first-in-man phase 1 clinical trials, 1308

World Congress of Dermatology, Syneron devices introduced at (PP), 805

Wound healingfrom basic science to clinical practice and

beyond (NVR), 427Cardium Therapeutics announces FDA 510(k)

clearance for Excellagen (PP), 1478case report of pyoderma gangrenosum


randomized double-blind petrolatum-controlled study on efficacy of oregano extract ointment in, 1168

secondary, in use of gelatin sponges in Mohs micrographic surgery defects and staged melanoma excisions, 68

Topix Pharmaceuticals releases Replenix ResurFIX Skin Barrier Healing Ointment (PP), 805

treatment efficacy of triple bandage compression and chitosan gel in venous leg ulcers, 75


Wrinklesazficel-T in nasolabial folds and wrinkles (PP),

325, 939comparing clinical attributes of

abobotulinumtoxinA and onabotulinumtoxinA using Frontalis Rating Scale and Frontalis Activity Measurement Standard, 1148

comparison of retinol 1.0% and tretinoin 0.02% in moderate-to-severe photodamage and wrinkles (CTR), 1217


Crutchfield Dermatology now offers Selphyl wrinkle treatment (PP), 213

efficacy and tolerability of new monophasic double-crosslinked hyaluronic acid filler for deep lines and, 134

efficacy of cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment, 990


FDA approval for Syneron LED-based skin rejuvenation system (PP), 435

FDA approval of Xeomin (incobotulinumtoxinA) for glabellar lines (PP), 1076

histological and immunohistochemical evaluation of intense pulsed light photorejuvenation for, 1246

La Roche-Posay introduces new products (PP), 938



safety and effectiveness of small and large gel-particle hyaluronic acid in correction of perioral wrinkles, 982


solid hyaluronic acid tailored to fix fine wrinkles (PP), 1341

Taenda Luxe Device for home treatment of periorbital wrinkles (PP), 1215

topical neurotoxin erases crow’s feet (PP), 1341


WS-1 fibroblast cells, complementary antioxidant function of caffeine and green tea polyphenols in normal human skin fibroblasts, 753

ZZanolimumab, study of human monoclonal

antibody to treat mycosis fungoides and Sézary syndrome (CTR), 1077

Zincand copper in natural therapies for

hyperpigmentation, s18 (September)

randomized double-blind placebo-controlled multi-center trial of zinc for herpes simplex labialis, 1343

ZK245186 in atopic dermatitis, efficacy and safety of different concentrations (CTR), 313

Zoster, herpes zoster vaccine reduces zoster risk (PP), 324

Zymosan, taurine chloramine inhibits NO and TNF-a production in zymosan plus interferon-g activated RAW 264.7 cells, 659

go green, go online! jddonlinedl.jddonline.com/pdfs/indexes/2011_subject_index.pdf · dutasteride...

Documents